20-F 1 tak-20210331.htm 20-F tak-20210331
00013950642021FYfalse33.3333.3333.3333.3333.3333.3333.3333.3333.3333.3333.3333.3300013950642020-04-012021-03-310001395064dei:BusinessContactMember2020-04-012021-03-310001395064exch:XNYS2020-04-012021-03-310001395064exch:XNYStak:A0750SeniorNotesDue2027Member2020-04-012021-03-310001395064exch:XNYStak:A1000SeniorNotesDue2029Member2020-04-012021-03-310001395064exch:XNYStak:A1375SeniorNotesDue2032Member2020-04-012021-03-310001395064exch:XNYStak:A2000SeniorNotesDue2040Member2020-04-012021-03-31xbrli:shares0001395064tak:ADSMember2021-03-310001395064ifrs-full:OrdinarySharesMember2021-03-31iso4217:JPY00013950642018-04-012019-03-3100013950642019-04-012020-03-31iso4217:JPYxbrli:shares00013950642020-03-3100013950642021-03-310001395064ifrs-full:IssuedCapitalMember2018-03-310001395064ifrs-full:SharePremiumMember2018-03-310001395064ifrs-full:TreasurySharesMember2018-03-310001395064ifrs-full:RetainedEarningsMember2018-03-310001395064ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2018-03-310001395064ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2018-03-310001395064ifrs-full:ReserveOfGainsAndLossesOnRemeasuringAvailableforsaleFinancialAssetsMember2018-03-310001395064ifrs-full:ReserveOfCashFlowHedgesMember2018-03-310001395064tak:ReserveOfHedgingCostMember2018-03-310001395064ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember2018-03-310001395064ifrs-full:OtherReservesMember2018-03-310001395064tak:ReserveOfRemeasurementsOfAssetsHeldForSaleMember2018-03-310001395064ifrs-full:EquityAttributableToOwnersOfParentMember2018-03-310001395064ifrs-full:NoncontrollingInterestsMember2018-03-3100013950642018-03-310001395064ifrs-full:RetainedEarningsMember2018-04-012019-03-310001395064ifrs-full:OtherReservesMember2018-04-012019-03-310001395064ifrs-full:EquityAttributableToOwnersOfParentMember2018-04-012019-03-310001395064ifrs-full:NoncontrollingInterestsMember2018-04-012019-03-310001395064ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2018-04-012019-03-310001395064ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2018-04-012019-03-310001395064ifrs-full:ReserveOfCashFlowHedgesMember2018-04-012019-03-310001395064tak:ReserveOfHedgingCostMember2018-04-012019-03-310001395064ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember2018-04-012019-03-310001395064tak:ReserveOfRemeasurementsOfAssetsHeldForSaleMember2018-04-012019-03-310001395064ifrs-full:IssuedCapitalMember2018-04-012019-03-310001395064ifrs-full:SharePremiumMember2018-04-012019-03-310001395064ifrs-full:TreasurySharesMember2018-04-012019-03-310001395064ifrs-full:IssuedCapitalMember2019-03-310001395064ifrs-full:SharePremiumMember2019-03-310001395064ifrs-full:TreasurySharesMember2019-03-310001395064ifrs-full:RetainedEarningsMember2019-03-310001395064ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2019-03-310001395064ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2019-03-310001395064ifrs-full:ReserveOfGainsAndLossesOnRemeasuringAvailableforsaleFinancialAssetsMember2019-03-310001395064ifrs-full:ReserveOfCashFlowHedgesMember2019-03-310001395064tak:ReserveOfHedgingCostMember2019-03-310001395064ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember2019-03-310001395064ifrs-full:OtherReservesMember2019-03-310001395064tak:ReserveOfRemeasurementsOfAssetsHeldForSaleMember2019-03-310001395064ifrs-full:EquityAttributableToOwnersOfParentMember2019-03-310001395064ifrs-full:NoncontrollingInterestsMember2019-03-3100013950642019-03-310001395064ifrs-full:RetainedEarningsMember2019-04-012020-03-310001395064ifrs-full:OtherReservesMember2019-04-012020-03-310001395064ifrs-full:EquityAttributableToOwnersOfParentMember2019-04-012020-03-310001395064ifrs-full:NoncontrollingInterestsMember2019-04-012020-03-310001395064ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2019-04-012020-03-310001395064ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2019-04-012020-03-310001395064ifrs-full:ReserveOfCashFlowHedgesMember2019-04-012020-03-310001395064tak:ReserveOfHedgingCostMember2019-04-012020-03-310001395064ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember2019-04-012020-03-310001395064ifrs-full:IssuedCapitalMember2019-04-012020-03-310001395064ifrs-full:SharePremiumMember2019-04-012020-03-310001395064ifrs-full:TreasurySharesMember2019-04-012020-03-310001395064ifrs-full:IssuedCapitalMember2020-03-310001395064ifrs-full:SharePremiumMember2020-03-310001395064ifrs-full:TreasurySharesMember2020-03-310001395064ifrs-full:RetainedEarningsMember2020-03-310001395064ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-03-310001395064ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2020-03-310001395064ifrs-full:ReserveOfCashFlowHedgesMember2020-03-310001395064tak:ReserveOfHedgingCostMember2020-03-310001395064ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember2020-03-310001395064ifrs-full:OtherReservesMember2020-03-310001395064ifrs-full:EquityAttributableToOwnersOfParentMember2020-03-310001395064ifrs-full:NoncontrollingInterestsMember2020-03-310001395064ifrs-full:RetainedEarningsMember2020-04-012021-03-310001395064ifrs-full:OtherReservesMember2020-04-012021-03-310001395064ifrs-full:EquityAttributableToOwnersOfParentMember2020-04-012021-03-310001395064ifrs-full:NoncontrollingInterestsMember2020-04-012021-03-310001395064ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-04-012021-03-310001395064ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2020-04-012021-03-310001395064ifrs-full:ReserveOfCashFlowHedgesMember2020-04-012021-03-310001395064tak:ReserveOfHedgingCostMember2020-04-012021-03-310001395064ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember2020-04-012021-03-310001395064ifrs-full:IssuedCapitalMember2020-04-012021-03-310001395064ifrs-full:SharePremiumMember2020-04-012021-03-310001395064ifrs-full:TreasurySharesMember2020-04-012021-03-310001395064ifrs-full:IssuedCapitalMember2021-03-310001395064ifrs-full:SharePremiumMember2021-03-310001395064ifrs-full:TreasurySharesMember2021-03-310001395064ifrs-full:RetainedEarningsMember2021-03-310001395064ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-03-310001395064ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2021-03-310001395064ifrs-full:ReserveOfCashFlowHedgesMember2021-03-310001395064tak:ReserveOfHedgingCostMember2021-03-310001395064ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember2021-03-310001395064ifrs-full:OtherReservesMember2021-03-310001395064ifrs-full:EquityAttributableToOwnersOfParentMember2021-03-310001395064ifrs-full:NoncontrollingInterestsMember2021-03-310001395064ifrs-full:BuildingsMemberifrs-full:BottomOfRangeMember2020-04-012021-03-310001395064ifrs-full:TopOfRangeMemberifrs-full:BuildingsMember2020-04-012021-03-310001395064tak:MachineryAndVehiclesMemberifrs-full:BottomOfRangeMember2020-04-012021-03-310001395064tak:MachineryAndVehiclesMemberifrs-full:TopOfRangeMember2020-04-012021-03-310001395064ifrs-full:FixturesAndFittingsMemberifrs-full:BottomOfRangeMember2020-04-012021-03-310001395064ifrs-full:TopOfRangeMemberifrs-full:FixturesAndFittingsMember2020-04-012021-03-310001395064ifrs-full:BottomOfRangeMembertak:MarketedProductsMember2020-04-012021-03-310001395064ifrs-full:TopOfRangeMembertak:MarketedProductsMember2020-04-012021-03-310001395064ifrs-full:ComputerSoftwareMemberifrs-full:BottomOfRangeMember2020-04-012021-03-310001395064ifrs-full:TopOfRangeMemberifrs-full:ComputerSoftwareMember2020-04-012021-03-310001395064tak:PharmaceuticalProductsMember2018-04-012019-03-310001395064tak:PharmaceuticalProductsMember2019-04-012020-03-310001395064tak:PharmaceuticalProductsMember2020-04-012021-03-310001395064tak:RoyaltyAndServicesMember2018-04-012019-03-310001395064tak:RoyaltyAndServicesMember2019-04-012020-03-310001395064tak:RoyaltyAndServicesMember2020-04-012021-03-310001395064tak:EntyvioMember2018-04-012019-03-310001395064tak:EntyvioMember2019-04-012020-03-310001395064tak:EntyvioMember2020-04-012021-03-310001395064tak:TakecabFMember2018-04-012019-03-310001395064tak:TakecabFMember2019-04-012020-03-310001395064tak:TakecabFMember2020-04-012021-03-310001395064tak:GattexRevestiveMember2018-04-012019-03-310001395064tak:GattexRevestiveMember2019-04-012020-03-310001395064tak:GattexRevestiveMember2020-04-012021-03-310001395064tak:DexilantMember2018-04-012019-03-310001395064tak:DexilantMember2019-04-012020-03-310001395064tak:DexilantMember2020-04-012021-03-310001395064tak:PANTOPRAZOLEMember2018-04-012019-03-310001395064tak:PANTOPRAZOLEMember2019-04-012020-03-310001395064tak:PANTOPRAZOLEMember2020-04-012021-03-310001395064tak:AlofiselMember2018-04-012019-03-310001395064tak:AlofiselMember2019-04-012020-03-310001395064tak:AlofiselMember2020-04-012021-03-310001395064tak:OtherGastroenterologyMember2018-04-012019-03-310001395064tak:OtherGastroenterologyMember2019-04-012020-03-310001395064tak:OtherGastroenterologyMember2020-04-012021-03-310001395064tak:GastroenterologyMember2018-04-012019-03-310001395064tak:GastroenterologyMember2019-04-012020-03-310001395064tak:GastroenterologyMember2020-04-012021-03-310001395064tak:ElapraseMember2018-04-012019-03-310001395064tak:ElapraseMember2019-04-012020-03-310001395064tak:ElapraseMember2020-04-012021-03-310001395064tak:ReplagalMember2018-04-012019-03-310001395064tak:ReplagalMember2019-04-012020-03-310001395064tak:ReplagalMember2020-04-012021-03-310001395064tak:VprivMember2018-04-012019-03-310001395064tak:VprivMember2019-04-012020-03-310001395064tak:VprivMember2020-04-012021-03-310001395064tak:NatparaMember2018-04-012019-03-310001395064tak:NatparaMember2019-04-012020-03-310001395064tak:NatparaMember2020-04-012021-03-310001395064tak:RareMetabolicMember2018-04-012019-03-310001395064tak:RareMetabolicMember2019-04-012020-03-310001395064tak:RareMetabolicMember2020-04-012021-03-310001395064tak:AdvateMember2018-04-012019-03-310001395064tak:AdvateMember2019-04-012020-03-310001395064tak:AdvateMember2020-04-012021-03-310001395064tak:AdynovateMember2018-04-012019-03-310001395064tak:AdynovateMember2019-04-012020-03-310001395064tak:AdynovateMember2020-04-012021-03-310001395064tak:FEIBAMember2018-04-012019-03-310001395064tak:FEIBAMember2019-04-012020-03-310001395064tak:FEIBAMember2020-04-012021-03-310001395064tak:RECOMBINATEMember2018-04-012019-03-310001395064tak:RECOMBINATEMember2019-04-012020-03-310001395064tak:RECOMBINATEMember2020-04-012021-03-310001395064tak:OtherRareHematologyMember2018-04-012019-03-310001395064tak:OtherRareHematologyMember2019-04-012020-03-310001395064tak:OtherRareHematologyMember2020-04-012021-03-310001395064tak:RareHematologyMember2018-04-012019-03-310001395064tak:RareHematologyMember2019-04-012020-03-310001395064tak:RareHematologyMember2020-04-012021-03-310001395064tak:TakhzyroMember2018-04-012019-03-310001395064tak:TakhzyroMember2019-04-012020-03-310001395064tak:TakhzyroMember2020-04-012021-03-310001395064tak:FirazyrMember2018-04-012019-03-310001395064tak:FirazyrMember2019-04-012020-03-310001395064tak:FirazyrMember2020-04-012021-03-310001395064tak:OtherHereditaryAngioedemaMember2018-04-012019-03-310001395064tak:OtherHereditaryAngioedemaMember2019-04-012020-03-310001395064tak:OtherHereditaryAngioedemaMember2020-04-012021-03-310001395064tak:HereditaryAngioedemaMember2018-04-012019-03-310001395064tak:HereditaryAngioedemaMember2019-04-012020-03-310001395064tak:HereditaryAngioedemaMember2020-04-012021-03-310001395064tak:RareDiseasesMember2018-04-012019-03-310001395064tak:RareDiseasesMember2019-04-012020-03-310001395064tak:RareDiseasesMember2020-04-012021-03-310001395064tak:ImmunoglobulinMember2018-04-012019-03-310001395064tak:ImmunoglobulinMember2019-04-012020-03-310001395064tak:ImmunoglobulinMember2020-04-012021-03-310001395064tak:AlbuminMember2018-04-012019-03-310001395064tak:AlbuminMember2019-04-012020-03-310001395064tak:AlbuminMember2020-04-012021-03-310001395064tak:OtherPDTImmunologyMember2018-04-012019-03-310001395064tak:OtherPDTImmunologyMember2019-04-012020-03-310001395064tak:OtherPDTImmunologyMember2020-04-012021-03-310001395064tak:PDTImmunologyMember2018-04-012019-03-310001395064tak:PDTImmunologyMember2019-04-012020-03-310001395064tak:PDTImmunologyMember2020-04-012021-03-310001395064tak:VelcadeMember2018-04-012019-03-310001395064tak:VelcadeMember2019-04-012020-03-310001395064tak:VelcadeMember2020-04-012021-03-310001395064tak:LeuprorelinMember2018-04-012019-03-310001395064tak:LeuprorelinMember2019-04-012020-03-310001395064tak:LeuprorelinMember2020-04-012021-03-310001395064tak:NinlaroMember2018-04-012019-03-310001395064tak:NinlaroMember2019-04-012020-03-310001395064tak:NinlaroMember2020-04-012021-03-310001395064tak:AdcetrisMember2018-04-012019-03-310001395064tak:AdcetrisMember2019-04-012020-03-310001395064tak:AdcetrisMember2020-04-012021-03-310001395064tak:IclusigMember2018-04-012019-03-310001395064tak:IclusigMember2019-04-012020-03-310001395064tak:IclusigMember2020-04-012021-03-310001395064tak:AlunbrigMember2018-04-012019-03-310001395064tak:AlunbrigMember2019-04-012020-03-310001395064tak:AlunbrigMember2020-04-012021-03-310001395064tak:OtherOncologyMember2018-04-012019-03-310001395064tak:OtherOncologyMember2019-04-012020-03-310001395064tak:OtherOncologyMember2020-04-012021-03-310001395064tak:OncologyMember2018-04-012019-03-310001395064tak:OncologyMember2019-04-012020-03-310001395064tak:OncologyMember2020-04-012021-03-310001395064tak:VyvanseMember2018-04-012019-03-310001395064tak:VyvanseMember2019-04-012020-03-310001395064tak:VyvanseMember2020-04-012021-03-310001395064tak:TrintellixMember2018-04-012019-03-310001395064tak:TrintellixMember2019-04-012020-03-310001395064tak:TrintellixMember2020-04-012021-03-310001395064tak:OtherNeuroscienceMember2018-04-012019-03-310001395064tak:OtherNeuroscienceMember2019-04-012020-03-310001395064tak:OtherNeuroscienceMember2020-04-012021-03-310001395064tak:NeuroscienceMember2018-04-012019-03-310001395064tak:NeuroscienceMember2019-04-012020-03-310001395064tak:NeuroscienceMember2020-04-012021-03-310001395064tak:AzilvaFMember2018-04-012019-03-310001395064tak:AzilvaFMember2019-04-012020-03-310001395064tak:AzilvaFMember2020-04-012021-03-310001395064tak:NesinaFMember2018-04-012019-03-310001395064tak:NesinaFMember2019-04-012020-03-310001395064tak:NesinaFMember2020-04-012021-03-310001395064tak:LotrigaMember2018-04-012019-03-310001395064tak:LotrigaMember2019-04-012020-03-310001395064tak:LotrigaMember2020-04-012021-03-310001395064tak:OtherProductOtherMember2018-04-012019-03-310001395064tak:OtherProductOtherMember2019-04-012020-03-310001395064tak:OtherProductOtherMember2020-04-012021-03-310001395064tak:OtherProductMember2018-04-012019-03-310001395064tak:OtherProductMember2019-04-012020-03-310001395064tak:OtherProductMember2020-04-012021-03-310001395064country:JP2018-04-012019-03-310001395064country:US2018-04-012019-03-310001395064tak:EuropeAndCanadaMember2018-04-012019-03-310001395064tak:RussianFederationAndCommonwealthOfIndependentStatesMember2018-04-012019-03-310001395064srt:LatinAmericaMember2018-04-012019-03-310001395064srt:AsiaMember2018-04-012019-03-310001395064tak:OtherCountriesNotSeparatelyReportedMember2018-04-012019-03-310001395064country:JP2019-04-012020-03-310001395064country:US2019-04-012020-03-310001395064tak:EuropeAndCanadaMember2019-04-012020-03-310001395064tak:RussianFederationAndCommonwealthOfIndependentStatesMember2019-04-012020-03-310001395064srt:LatinAmericaMember2019-04-012020-03-310001395064srt:AsiaMember2019-04-012020-03-310001395064tak:OtherCountriesNotSeparatelyReportedMember2019-04-012020-03-310001395064country:JP2020-04-012021-03-310001395064country:US2020-04-012021-03-310001395064tak:EuropeAndCanadaMember2020-04-012021-03-310001395064tak:RussianFederationAndCommonwealthOfIndependentStatesMember2020-04-012021-03-310001395064srt:LatinAmericaMember2020-04-012021-03-310001395064srt:AsiaMember2020-04-012021-03-310001395064tak:OtherCountriesNotSeparatelyReportedMember2020-04-012021-03-310001395064country:JP2020-03-310001395064country:US2020-03-310001395064country:CH2020-03-310001395064tak:OtherCountriesNotSeparatelyReportedMember2020-03-310001395064country:JP2021-03-310001395064country:US2021-03-310001395064country:CH2021-03-310001395064tak:OtherCountriesNotSeparatelyReportedMember2021-03-310001395064tak:MedipalHoldingsCorporationAndSubsidiariesMembertak:ConcentrationOfRiskNetSalesMember2018-04-012019-03-310001395064tak:ConcentrationOfRiskNetSalesMembertak:AmerisourceBergenCorporationMember2019-04-012020-03-310001395064tak:ConcentrationOfRiskNetSalesMembertak:AmerisourceBergenCorporationMember2020-04-012021-03-310001395064tak:ConcentrationOfRiskNetSalesMembertak:McKessonCorporationMember2019-04-012020-03-310001395064tak:ConcentrationOfRiskNetSalesMembertak:McKessonCorporationMember2020-04-012021-03-310001395064ifrs-full:NotLaterThanOneYearMember2020-03-310001395064ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2020-03-310001395064ifrs-full:LaterThanFiveYearsMember2020-03-310001395064ifrs-full:NotLaterThanOneYearMember2021-03-310001395064ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2021-03-310001395064ifrs-full:LaterThanFiveYearsMember2021-03-310001395064tak:TevaTakedaPharmaLtd.Member2018-04-012019-03-310001395064tak:TevaTakedaPharmaLtd.Member2019-04-012020-03-310001395064tak:TevaTakedaPharmaLtd.Member2020-04-012021-03-31xbrli:pure0001395064tak:GuangdongTechpoolBioPharmaCo.Ltd.Member2018-04-012019-03-310001395064ifrs-full:LegalProceedingsProvisionMember2020-04-012021-03-310001395064tak:EnhancedPriorYearCreditClaimsMember2019-04-012020-03-310001395064country:CH2019-04-012020-03-310001395064country:CH2020-04-012021-03-310001395064tak:ResearchAndDevelopmentRelatedTemporaryDifferencesMember2019-03-310001395064tak:ResearchAndDevelopmentRelatedTemporaryDifferencesMember2019-04-012020-03-310001395064tak:ResearchAndDevelopmentRelatedTemporaryDifferencesMember2020-03-310001395064tak:InventoryRelatedTemporaryDifferencesMember2019-03-310001395064tak:InventoryRelatedTemporaryDifferencesMember2019-04-012020-03-310001395064tak:InventoryRelatedTemporaryDifferencesMember2020-03-310001395064tak:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember2019-03-310001395064tak:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember2019-04-012020-03-310001395064tak:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember2020-03-310001395064tak:IntangibleAssetRelatedTemporaryDifferencesMember2019-03-310001395064tak:IntangibleAssetRelatedTemporaryDifferencesMember2019-04-012020-03-310001395064tak:IntangibleAssetRelatedTemporaryDifferencesMember2020-03-310001395064tak:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2019-03-310001395064tak:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2019-04-012020-03-310001395064tak:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2020-03-310001395064tak:AccruedExpensesAndProvisionsRelatedTemporaryDifferencesMember2019-03-310001395064tak:AccruedExpensesAndProvisionsRelatedTemporaryDifferencesMember2019-04-012020-03-310001395064tak:AccruedExpensesAndProvisionsRelatedTemporaryDifferencesMember2020-03-310001395064tak:DefinedBenefitPlanRelatedTemporaryDifferencesMember2019-03-310001395064tak:DefinedBenefitPlanRelatedTemporaryDifferencesMember2019-04-012020-03-310001395064tak:DefinedBenefitPlanRelatedTemporaryDifferencesMember2020-03-310001395064tak:DeferredIncomeRelatedTemporaryDifferencesMember2019-03-310001395064tak:DeferredIncomeRelatedTemporaryDifferencesMember2019-04-012020-03-310001395064tak:DeferredIncomeRelatedTemporaryDifferencesMember2020-03-310001395064ifrs-full:UnusedTaxLossesMember2019-03-310001395064ifrs-full:UnusedTaxLossesMember2019-04-012020-03-310001395064ifrs-full:UnusedTaxLossesMember2020-03-310001395064ifrs-full:UnusedTaxCreditsMember2019-03-310001395064ifrs-full:UnusedTaxCreditsMember2019-04-012020-03-310001395064ifrs-full:UnusedTaxCreditsMember2020-03-310001395064tak:InvestmentsInAffiliatedEntityRelatedTemporaryDifferencesMember2019-03-310001395064tak:InvestmentsInAffiliatedEntityRelatedTemporaryDifferencesMember2019-04-012020-03-310001395064tak:InvestmentsInAffiliatedEntityRelatedTemporaryDifferencesMember2020-03-310001395064ifrs-full:OtherTemporaryDifferencesMember2019-03-310001395064ifrs-full:OtherTemporaryDifferencesMember2019-04-012020-03-310001395064ifrs-full:OtherTemporaryDifferencesMember2020-03-310001395064tak:ResearchAndDevelopmentRelatedTemporaryDifferencesMember2020-04-012021-03-310001395064tak:ResearchAndDevelopmentRelatedTemporaryDifferencesMember2021-03-310001395064tak:InventoryRelatedTemporaryDifferencesMember2020-04-012021-03-310001395064tak:InventoryRelatedTemporaryDifferencesMember2021-03-310001395064tak:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember2020-04-012021-03-310001395064tak:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember2021-03-310001395064tak:IntangibleAssetRelatedTemporaryDifferencesMember2020-04-012021-03-310001395064tak:IntangibleAssetRelatedTemporaryDifferencesMember2021-03-310001395064tak:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2020-04-012021-03-310001395064tak:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2021-03-310001395064tak:AccruedExpensesAndProvisionsRelatedTemporaryDifferencesMember2020-04-012021-03-310001395064tak:AccruedExpensesAndProvisionsRelatedTemporaryDifferencesMember2021-03-310001395064tak:DefinedBenefitPlanRelatedTemporaryDifferencesMember2020-04-012021-03-310001395064tak:DefinedBenefitPlanRelatedTemporaryDifferencesMember2021-03-310001395064tak:DeferredIncomeRelatedTemporaryDifferencesMember2020-04-012021-03-310001395064tak:DeferredIncomeRelatedTemporaryDifferencesMember2021-03-310001395064ifrs-full:UnusedTaxLossesMember2020-04-012021-03-310001395064ifrs-full:UnusedTaxLossesMember2021-03-310001395064ifrs-full:UnusedTaxCreditsMember2020-04-012021-03-310001395064ifrs-full:UnusedTaxCreditsMember2021-03-310001395064tak:InvestmentsInAffiliatedEntityRelatedTemporaryDifferencesMember2020-04-012021-03-310001395064tak:InvestmentsInAffiliatedEntityRelatedTemporaryDifferencesMember2021-03-310001395064ifrs-full:OtherTemporaryDifferencesMember2020-04-012021-03-310001395064ifrs-full:OtherTemporaryDifferencesMember2021-03-310001395064ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2020-03-310001395064ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2021-03-310001395064ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2020-03-310001395064ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2021-03-310001395064ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2020-03-310001395064ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2021-03-310001395064ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2020-03-310001395064ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2021-03-310001395064tak:IndefiniteYearsMember2020-03-310001395064tak:IndefiniteYearsMember2021-03-310001395064ifrs-full:BuildingsMembertak:AcquisitionCostMemberifrs-full:PreviouslyStatedMember2019-03-310001395064tak:MachineryAndVehiclesMembertak:AcquisitionCostMemberifrs-full:PreviouslyStatedMember2019-03-310001395064ifrs-full:FixturesAndFittingsMembertak:AcquisitionCostMemberifrs-full:PreviouslyStatedMember2019-03-310001395064tak:AcquisitionCostMemberifrs-full:LandMemberifrs-full:PreviouslyStatedMember2019-03-310001395064tak:AcquisitionCostMemberifrs-full:ConstructionInProgressMemberifrs-full:PreviouslyStatedMember2019-03-310001395064tak:AcquisitionCostMemberifrs-full:PreviouslyStatedMember2019-03-310001395064ifrs-full:BuildingsMemberifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMembertak:AcquisitionCostMember2019-03-310001395064tak:MachineryAndVehiclesMemberifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMembertak:AcquisitionCostMember2019-03-310001395064ifrs-full:FixturesAndFittingsMemberifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMembertak:AcquisitionCostMember2019-03-310001395064ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMembertak:AcquisitionCostMemberifrs-full:LandMember2019-03-310001395064ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMembertak:AcquisitionCostMemberifrs-full:ConstructionInProgressMember2019-03-310001395064ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMembertak:AcquisitionCostMember2019-03-310001395064ifrs-full:BuildingsMembertak:AcquisitionCostMember2019-03-310001395064tak:MachineryAndVehiclesMembertak:AcquisitionCostMember2019-03-310001395064ifrs-full:FixturesAndFittingsMembertak:AcquisitionCostMember2019-03-310001395064tak:AcquisitionCostMemberifrs-full:LandMember2019-03-310001395064tak:AcquisitionCostMemberifrs-full:ConstructionInProgressMember2019-03-310001395064tak:AcquisitionCostMember2019-03-310001395064ifrs-full:BuildingsMembertak:AcquisitionCostMember2019-04-012020-03-310001395064tak:MachineryAndVehiclesMembertak:AcquisitionCostMember2019-04-012020-03-310001395064ifrs-full:FixturesAndFittingsMembertak:AcquisitionCostMember2019-04-012020-03-310001395064tak:AcquisitionCostMemberifrs-full:LandMember2019-04-012020-03-310001395064tak:AcquisitionCostMemberifrs-full:ConstructionInProgressMember2019-04-012020-03-310001395064tak:AcquisitionCostMember2019-04-012020-03-310001395064ifrs-full:BuildingsMembertak:AcquisitionCostMember2020-03-310001395064tak:MachineryAndVehiclesMembertak:AcquisitionCostMember2020-03-310001395064ifrs-full:FixturesAndFittingsMembertak:AcquisitionCostMember2020-03-310001395064tak:AcquisitionCostMemberifrs-full:LandMember2020-03-310001395064tak:AcquisitionCostMemberifrs-full:ConstructionInProgressMember2020-03-310001395064tak:AcquisitionCostMember2020-03-310001395064ifrs-full:BuildingsMembertak:AcquisitionCostMember2020-04-012021-03-310001395064tak:MachineryAndVehiclesMembertak:AcquisitionCostMember2020-04-012021-03-310001395064ifrs-full:FixturesAndFittingsMembertak:AcquisitionCostMember2020-04-012021-03-310001395064tak:AcquisitionCostMemberifrs-full:LandMember2020-04-012021-03-310001395064tak:AcquisitionCostMemberifrs-full:ConstructionInProgressMember2020-04-012021-03-310001395064tak:AcquisitionCostMember2020-04-012021-03-310001395064ifrs-full:BuildingsMembertak:AcquisitionCostMember2021-03-310001395064tak:MachineryAndVehiclesMembertak:AcquisitionCostMember2021-03-310001395064ifrs-full:FixturesAndFittingsMembertak:AcquisitionCostMember2021-03-310001395064tak:AcquisitionCostMemberifrs-full:LandMember2021-03-310001395064tak:AcquisitionCostMemberifrs-full:ConstructionInProgressMember2021-03-310001395064tak:AcquisitionCostMember2021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2019-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembertak:MachineryAndVehiclesMember2019-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:FixturesAndFittingsMember2019-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandMember2019-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ConstructionInProgressMember2019-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2019-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2019-04-012020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembertak:MachineryAndVehiclesMember2019-04-012020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:FixturesAndFittingsMember2019-04-012020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandMember2019-04-012020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ConstructionInProgressMember2019-04-012020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2019-04-012020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembertak:MachineryAndVehiclesMember2020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:FixturesAndFittingsMember2020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandMember2020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ConstructionInProgressMember2020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2020-04-012021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembertak:MachineryAndVehiclesMember2020-04-012021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:FixturesAndFittingsMember2020-04-012021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandMember2020-04-012021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ConstructionInProgressMember2020-04-012021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-04-012021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembertak:MachineryAndVehiclesMember2021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:FixturesAndFittingsMember2021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandMember2021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ConstructionInProgressMember2021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-03-310001395064ifrs-full:BuildingsMemberifrs-full:GrossCarryingAmountMember2019-03-310001395064tak:MachineryAndVehiclesMemberifrs-full:GrossCarryingAmountMember2019-03-310001395064ifrs-full:FixturesAndFittingsMemberifrs-full:GrossCarryingAmountMember2019-03-310001395064ifrs-full:LandMemberifrs-full:GrossCarryingAmountMember2019-03-310001395064ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2019-03-310001395064ifrs-full:GrossCarryingAmountMember2019-03-310001395064ifrs-full:BuildingsMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064tak:MachineryAndVehiclesMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064ifrs-full:FixturesAndFittingsMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064ifrs-full:LandMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2020-03-310001395064ifrs-full:GrossCarryingAmountMember2020-03-310001395064ifrs-full:BuildingsMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064tak:MachineryAndVehiclesMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064ifrs-full:FixturesAndFittingsMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064ifrs-full:LandMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2021-03-310001395064ifrs-full:GrossCarryingAmountMember2021-03-310001395064ifrs-full:BuildingsMembertak:AcquisitionCostMember2019-03-310001395064tak:MachineryAndVehiclesMembertak:AcquisitionCostMember2019-03-310001395064ifrs-full:FixturesAndFittingsMembertak:AcquisitionCostMember2019-03-310001395064ifrs-full:BuildingsMembertak:AcquisitionCostMember2019-04-012020-03-310001395064tak:MachineryAndVehiclesMembertak:AcquisitionCostMember2019-04-012020-03-310001395064ifrs-full:FixturesAndFittingsMembertak:AcquisitionCostMember2019-04-012020-03-310001395064ifrs-full:BuildingsMembertak:AcquisitionCostMember2020-03-310001395064tak:MachineryAndVehiclesMembertak:AcquisitionCostMember2020-03-310001395064ifrs-full:FixturesAndFittingsMembertak:AcquisitionCostMember2020-03-310001395064ifrs-full:BuildingsMembertak:AcquisitionCostMember2020-04-012021-03-310001395064tak:MachineryAndVehiclesMembertak:AcquisitionCostMember2020-04-012021-03-310001395064ifrs-full:FixturesAndFittingsMembertak:AcquisitionCostMember2020-04-012021-03-310001395064ifrs-full:BuildingsMembertak:AcquisitionCostMember2021-03-310001395064tak:MachineryAndVehiclesMembertak:AcquisitionCostMember2021-03-310001395064ifrs-full:FixturesAndFittingsMembertak:AcquisitionCostMember2021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2019-03-310001395064tak:MachineryAndVehiclesMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2019-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:FixturesAndFittingsMember2019-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2019-04-012020-03-310001395064tak:MachineryAndVehiclesMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2019-04-012020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:FixturesAndFittingsMember2019-04-012020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2020-03-310001395064tak:MachineryAndVehiclesMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:FixturesAndFittingsMember2020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2020-04-012021-03-310001395064tak:MachineryAndVehiclesMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-04-012021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:FixturesAndFittingsMember2020-04-012021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2021-03-310001395064tak:MachineryAndVehiclesMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:FixturesAndFittingsMember2021-03-310001395064ifrs-full:AccumulatedImpairmentMember2018-04-012019-03-310001395064ifrs-full:AccumulatedImpairmentMember2019-04-012020-03-310001395064ifrs-full:AccumulatedImpairmentMember2020-04-012021-03-310001395064ifrs-full:GoodwillMembertak:AcquisitionCostMember2019-03-310001395064ifrs-full:GoodwillMembertak:AcquisitionCostMember2020-03-310001395064ifrs-full:GoodwillMembertak:AcquisitionCostMember2019-04-012020-03-310001395064ifrs-full:GoodwillMembertak:AcquisitionCostMember2020-04-012021-03-310001395064ifrs-full:GoodwillMembertak:AcquisitionCostMember2021-03-310001395064ifrs-full:GoodwillMemberifrs-full:GrossCarryingAmountMember2019-03-310001395064ifrs-full:GoodwillMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064ifrs-full:GoodwillMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064ifrs-full:ComputerSoftwareMembertak:AcquisitionCostMember2019-03-310001395064tak:AcquisitionCostMembertak:ProductRelatedIntangibleAssetsMember2019-03-310001395064tak:AcquisitionCostMemberifrs-full:OtherIntangibleAssetsMember2019-03-310001395064ifrs-full:ComputerSoftwareMembertak:AcquisitionCostMember2019-04-012020-03-310001395064tak:AcquisitionCostMembertak:ProductRelatedIntangibleAssetsMember2019-04-012020-03-310001395064tak:AcquisitionCostMemberifrs-full:OtherIntangibleAssetsMember2019-04-012020-03-310001395064ifrs-full:ComputerSoftwareMembertak:AcquisitionCostMember2020-03-310001395064tak:AcquisitionCostMembertak:ProductRelatedIntangibleAssetsMember2020-03-310001395064tak:AcquisitionCostMemberifrs-full:OtherIntangibleAssetsMember2020-03-310001395064ifrs-full:ComputerSoftwareMembertak:AcquisitionCostMember2020-04-012021-03-310001395064tak:AcquisitionCostMembertak:ProductRelatedIntangibleAssetsMember2020-04-012021-03-310001395064tak:AcquisitionCostMemberifrs-full:OtherIntangibleAssetsMember2020-04-012021-03-310001395064ifrs-full:ComputerSoftwareMembertak:AcquisitionCostMember2021-03-310001395064tak:AcquisitionCostMembertak:ProductRelatedIntangibleAssetsMember2021-03-310001395064tak:AcquisitionCostMemberifrs-full:OtherIntangibleAssetsMember2021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerSoftwareMember2019-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembertak:ProductRelatedIntangibleAssetsMember2019-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherIntangibleAssetsMember2019-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerSoftwareMember2019-04-012020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembertak:ProductRelatedIntangibleAssetsMember2019-04-012020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherIntangibleAssetsMember2019-04-012020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerSoftwareMember2020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembertak:ProductRelatedIntangibleAssetsMember2020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherIntangibleAssetsMember2020-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerSoftwareMember2020-04-012021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembertak:ProductRelatedIntangibleAssetsMember2020-04-012021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherIntangibleAssetsMember2020-04-012021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerSoftwareMember2021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembertak:ProductRelatedIntangibleAssetsMember2021-03-310001395064ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherIntangibleAssetsMember2021-03-310001395064ifrs-full:ComputerSoftwareMemberifrs-full:GrossCarryingAmountMember2019-03-310001395064tak:ProductRelatedIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2019-03-310001395064ifrs-full:OtherIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2019-03-310001395064ifrs-full:ComputerSoftwareMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064tak:ProductRelatedIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064ifrs-full:OtherIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064ifrs-full:ComputerSoftwareMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064tak:ProductRelatedIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064ifrs-full:OtherIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMemberifrs-full:GrossCarryingAmountMember2019-03-310001395064tak:InProcessResearchAndDevelopmentMemberifrs-full:GrossCarryingAmountMember2019-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064tak:InProcessResearchAndDevelopmentMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064tak:InProcessResearchAndDevelopmentMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMembertak:ImmunoglobulinMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMembertak:ImmunoglobulinMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMembertak:ImmunoglobulinMemberifrs-full:GrossCarryingAmountMember2020-04-012021-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMembertak:TakhzyroMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMembertak:TakhzyroMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMembertak:TakhzyroMemberifrs-full:GrossCarryingAmountMember2020-04-012021-03-310001395064tak:VyvanseMembertak:MarketedProductsIntangibleAssetsOtherThanGoodwillMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064tak:VyvanseMembertak:MarketedProductsIntangibleAssetsOtherThanGoodwillMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064tak:VyvanseMembertak:MarketedProductsIntangibleAssetsOtherThanGoodwillMemberifrs-full:GrossCarryingAmountMember2020-04-012021-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMembertak:ADVATEAndADYNOVATEMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMembertak:ADVATEAndADYNOVATEMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMembertak:ADVATEAndADYNOVATEMemberifrs-full:GrossCarryingAmountMember2020-04-012021-03-310001395064tak:InProcessResearchAndDevelopmentMembertak:AlunbrigMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064tak:InProcessResearchAndDevelopmentMembertak:AlunbrigMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMembertak:AlunbrigMemberifrs-full:GrossCarryingAmountMember2020-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMembertak:AlunbrigMemberifrs-full:GrossCarryingAmountMember2021-03-310001395064tak:MarketedProductsIntangibleAssetsOtherThanGoodwillMembertak:AlunbrigMemberifrs-full:GrossCarryingAmountMember2020-04-012021-03-310001395064tak:ImpairedProductRelatedIntangibleAssetsMember2019-03-310001395064tak:ImpairedProductRelatedIntangibleAssetsMember2020-03-310001395064tak:ImpairedProductRelatedIntangibleAssetsMember2021-03-310001395064tak:IntangibleAssetsOtherThanGoodwillPostTaxMember2019-03-310001395064tak:IntangibleAssetsOtherThanGoodwillPostTaxMembersrt:MinimumMember2021-03-310001395064tak:IntangibleAssetsOtherThanGoodwillPostTaxMembersrt:MaximumMember2021-03-310001395064tak:IntangibleAssetsOtherThanGoodwillPostTaxMember2021-03-310001395064tak:NeurocrineBiosciencesIncMember2020-06-012020-06-300001395064tak:RaniTherapeuticsLLCMember2019-01-310001395064tak:ArrowheadPharmaceuticalsIncMember2020-10-012020-10-310001395064tak:TevaTakedaPharmaLtd.Member2016-04-010001395064tak:TevaTakedaPharmaLtd.Member2021-03-310001395064tak:TevaTakedaPharmaLtd.Member2016-04-012016-04-010001395064tak:TevaTakedaPharmaLtd.Member2018-04-012019-03-310001395064tak:TevaTakedaPharmaLtd.Member2019-04-012020-03-310001395064tak:TevaTakedaPharmaLtd.Member2020-04-012021-03-310001395064tak:TevaTakedaPharmaLtd.Member2020-03-310001395064ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2018-04-012019-03-310001395064ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2019-04-012020-03-310001395064ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2020-04-012021-03-310001395064ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2020-03-310001395064ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2021-03-310001395064tak:ConvertibleNotesMember2020-03-310001395064tak:ConvertibleNotesMember2021-03-310001395064ifrs-full:DebtSecuritiesMember2020-03-310001395064ifrs-full:DebtSecuritiesMember2021-03-310001395064ifrs-full:Level1OfFairValueHierarchyMember2020-03-310001395064ifrs-full:Level1OfFairValueHierarchyMember2021-03-310001395064ifrs-full:DisposalGroupsClassifiedAsHeldForSaleMember2020-03-310001395064ifrs-full:DisposalGroupsClassifiedAsHeldForSaleMember2021-03-310001395064tak:XiidraMemberifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember2019-04-012020-03-310001395064tak:PharmaceuticalProductsMemberifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember2019-04-012020-03-310001395064ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember2019-04-012020-03-310001395064tak:ShonanHealthInnovationParkMember2020-09-30tak:site0001395064tak:TakedaConsumerHealthcareCompanyLimitedMemberifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember2020-04-012021-03-310001395064tak:UnsecuredStraightBonds15thMember2021-03-310001395064tak:UnsecuredStraightBonds15thMember2020-03-310001395064tak:HybridSubordinatedBondsMember2021-03-310001395064tak:HybridSubordinatedBondsMember2020-03-310001395064tak:HybridSubordinatedBondsMembersrt:MinimumMembertak:LondonInterbankOfferedRateLIBORMember2021-03-310001395064tak:HybridSubordinatedBondsMembersrt:MaximumMembertak:LondonInterbankOfferedRateLIBORMember2021-03-31iso4217:USD0001395064tak:USDUnsecuredSeniorNotesMember2021-03-310001395064tak:USDUnsecuredSeniorNotesMember2020-03-31iso4217:EUR0001395064tak:SeniorNotes2018EURVariableRateMember2020-03-310001395064tak:SeniorNotes2018EURVariableRateMember2021-03-310001395064tak:SeniorNotes2018EURVariableRateMembertak:EURIBORRateMembersrt:MinimumMember2020-03-310001395064tak:SeniorNotes2018EURVariableRateMembertak:EURIBORRateMembersrt:MaximumMember2020-03-310001395064tak:SeniorNotes2018EURVariableRateMembertak:EURIBORRateMember2021-03-310001395064tak:SeniorNotes2018EURFixedRateMember2020-03-310001395064tak:SeniorNotes2018EURFixedRateMember2021-03-310001395064srt:MinimumMembertak:SeniorNotes2018EURFixedRateMember2020-03-310001395064srt:MaximumMembertak:SeniorNotes2018EURFixedRateMember2020-03-310001395064srt:MinimumMembertak:SeniorNotes2018EURFixedRateMember2021-03-310001395064srt:MaximumMembertak:SeniorNotes2018EURFixedRateMember2021-03-310001395064tak:SeniorNotes2018USDFixedRateMember2021-03-310001395064tak:SeniorNotes2018USDFixedRateMember2020-03-310001395064srt:MinimumMembertak:SeniorNotes2018USDFixedRateMember2020-03-310001395064srt:MaximumMembertak:SeniorNotes2018USDFixedRateMember2020-03-310001395064srt:MinimumMembertak:SeniorNotes2018USDFixedRateMember2021-03-310001395064srt:MaximumMembertak:SeniorNotes2018USDFixedRateMember2021-03-310001395064tak:UnsecuredSeniorNotesDueSeptember2019ToSeptember2026Member2020-03-310001395064tak:UnsecuredSeniorNotesDueSeptember2019ToSeptember2026Member2021-03-310001395064tak:UnsecuredSeniorNotesDueSeptember2019ToSeptember2026Membersrt:MinimumMember2020-03-310001395064tak:UnsecuredSeniorNotesDueSeptember2019ToSeptember2026Membersrt:MaximumMember2020-03-310001395064tak:UnsecuredSeniorNotesDueSeptember2019ToSeptember2026Membersrt:MinimumMember2021-03-310001395064tak:UnsecuredSeniorNotesDueSeptember2019ToSeptember2026Membersrt:MaximumMember2021-03-310001395064tak:UnsecuredSeniorNotesDueJune2022ToJune2045Member2021-03-310001395064tak:UnsecuredSeniorNotesDueJune2022ToJune2045Member2020-03-310001395064tak:UnsecuredSeniorNotesDueJune2022ToJune2045Membersrt:MinimumMember2021-03-310001395064tak:UnsecuredSeniorNotesDueJune2022ToJune2045Membersrt:MaximumMember2021-03-310001395064tak:SeniorNotes2020USDUnsecuredSeniorNotesFixedRateMember2021-03-310001395064tak:SeniorNotes2020USDUnsecuredSeniorNotesFixedRateMember2020-03-310001395064srt:MinimumMembertak:SeniorNotes2020USDUnsecuredSeniorNotesFixedRateMember2021-03-310001395064srt:MaximumMembertak:SeniorNotes2020USDUnsecuredSeniorNotesFixedRateMember2021-03-310001395064tak:SeniorNotes2020EURUnsecuredSeniorNotesFixedRateMember2021-03-310001395064tak:SeniorNotes2020EURUnsecuredSeniorNotesFixedRateMember2020-03-310001395064tak:SeniorNotes2020EURUnsecuredSeniorNotesFixedRateMembersrt:MinimumMember2021-03-310001395064tak:SeniorNotes2020EURUnsecuredSeniorNotesFixedRateMembersrt:MaximumMember2021-03-310001395064tak:CommercialPaperMember2021-03-310001395064tak:CommercialPaperMember2020-03-310001395064tak:SyndicatedLoans2013Member2021-03-310001395064tak:SyndicatedLoans2013Member2020-03-310001395064tak:SyndicatedLoans2013Membertak:LondonInterbankOfferedRateLIBORMember2021-03-310001395064tak:SyndicatedLoans2016Member2021-03-310001395064tak:SyndicatedLoans2016Member2020-03-310001395064tak:SyndicatedLoans2016Membersrt:MinimumMember2021-03-310001395064tak:SyndicatedLoans2016Membersrt:MaximumMember2021-03-310001395064tak:SyndicatedLoans2017Member2021-03-310001395064tak:SyndicatedLoans2017Member2020-03-310001395064tak:SyndicatedLoansUSD2017Member2021-03-310001395064tak:SyndicatedLoansUSD2017Member2020-03-310001395064tak:LondonInterbankOfferedRateLIBORMembertak:SyndicatedLoansUSD2017Member2021-03-310001395064tak:SyndicatedLoans2019Member2021-03-310001395064tak:SyndicatedLoans2019Member2020-03-310001395064tak:SyndicatedLoans2019Membersrt:MinimumMember2021-03-310001395064tak:SyndicatedLoans2019Membersrt:MaximumMember2021-03-310001395064tak:USDJapanBankForInternationalCooperation2019Member2021-03-310001395064tak:USDJapanBankForInternationalCooperation2019Member2020-03-310001395064tak:USDJapanBankForInternationalCooperation2019Membertak:LondonInterbankOfferedRateLIBORMember2021-03-310001395064tak:LoansOtherMember2020-03-310001395064tak:LoansOtherMember2021-03-310001395064tak:SeniorNotes2020USDUnsecuredSeniorNotesFixedRateMember2020-07-090001395064tak:SeniorNotes2020EURUnsecuredSeniorNotesFixedRateMember2020-07-090001395064tak:USDSyndicatedLoansMember2020-07-102020-07-100001395064tak:EURSyndicatedLoansMember2020-07-102020-07-100001395064tak:USDUnsecuredSeniorNotesMember2020-08-032020-08-030001395064tak:EURUnsecuredSeniorNotesMember2020-08-032020-08-030001395064tak:USDUnsecuredSeniorNotesMember2021-01-222021-02-260001395064tak:USDUnsecuredSeniorNotesMember2021-02-262021-02-260001395064tak:USDUnsecuredSeniorNotesMember2021-01-222021-01-220001395064tak:USDUnsecuredSeniorNotesMember2021-02-252021-02-250001395064tak:USDAndEURTermLoanCreditAgreementMember2020-04-012020-04-300001395064tak:LoansAndUnsecuredStraightBondsIssuedJuly2013Member2020-07-012020-07-310001395064tak:LoansIssuedJuly2013Member2020-07-012020-07-310001395064tak:UnsecuredStraightBondsIssuedJuly2013Member2020-07-012020-07-310001395064tak:UnsecuredSeniorNotesDueSeptember2019ToSeptember2026Member2020-11-012020-11-300001395064tak:HybridSubordinatedBondsMember2019-06-060001395064tak:HybridSubordinatedBondsMembersrt:MinimumMembertak:LondonInterbankOfferedRateLIBORMember2019-06-060001395064tak:HybridSubordinatedBondsMembersrt:MaximumMembertak:LondonInterbankOfferedRateLIBORMember2019-06-0600013950642019-09-300001395064tak:CurrencyAndInterestRateSwapContractMembertak:SyndicatedLoansUSD2017Member2020-03-310001395064ifrs-full:InterestRateSwapContractMembertak:SyndicatedLoansUSD2017Member2020-03-310001395064tak:USDUnsecuredSeniorNotesMembertak:CurrencyAndInterestRateSwapContractMember2020-03-310001395064tak:CurrencyAndInterestRateSwapContractMembertak:SeniorNotes2018USDFixedRateMember2020-03-310001395064tak:CurrencyAndInterestRateSwapContractMembertak:SeniorNotes2020USDUnsecuredSeniorNotesFixedRateMember2020-03-310001395064ifrs-full:CountryOfDomicileMember2018-04-012019-03-310001395064ifrs-full:CountryOfDomicileMember2019-04-012020-03-310001395064ifrs-full:CountryOfDomicileMember2020-04-012021-03-310001395064ifrs-full:ForeignCountriesMember2018-04-012019-03-310001395064ifrs-full:ForeignCountriesMember2019-04-012020-03-310001395064ifrs-full:ForeignCountriesMember2020-04-012021-03-310001395064ifrs-full:CountryOfDomicileMember2020-03-310001395064ifrs-full:ForeignCountriesMember2020-03-310001395064ifrs-full:CountryOfDomicileMember2021-03-310001395064ifrs-full:ForeignCountriesMember2021-03-310001395064ifrs-full:EffectOfAssetCeilingMemberifrs-full:CountryOfDomicileMember2021-03-310001395064ifrs-full:EffectOfAssetCeilingMemberifrs-full:ForeignCountriesMember2021-03-310001395064ifrs-full:EffectOfAssetCeilingMember2021-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMemberifrs-full:CountryOfDomicileMember2019-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMemberifrs-full:ForeignCountriesMember2019-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMember2019-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMemberifrs-full:CountryOfDomicileMember2019-04-012020-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMemberifrs-full:ForeignCountriesMember2019-04-012020-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMember2019-04-012020-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMemberifrs-full:CountryOfDomicileMember2020-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMemberifrs-full:ForeignCountriesMember2020-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMember2020-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMemberifrs-full:CountryOfDomicileMember2020-04-012021-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMemberifrs-full:ForeignCountriesMember2020-04-012021-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMember2020-04-012021-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMemberifrs-full:CountryOfDomicileMember2021-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMemberifrs-full:ForeignCountriesMember2021-03-310001395064ifrs-full:PresentValueOfDefinedBenefitObligationMember2021-03-310001395064ifrs-full:ActuarialAssumptionOfDiscountRatesMemberifrs-full:CountryOfDomicileMember2020-03-310001395064ifrs-full:CountryOfDomicileMemberifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember2020-03-310001395064ifrs-full:ActuarialAssumptionOfDiscountRatesMemberifrs-full:ForeignCountriesMember2020-03-310001395064ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMemberifrs-full:ForeignCountriesMember2020-03-310001395064ifrs-full:ActuarialAssumptionOfDiscountRatesMemberifrs-full:CountryOfDomicileMember2021-03-310001395064ifrs-full:CountryOfDomicileMemberifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember2021-03-310001395064ifrs-full:ActuarialAssumptionOfDiscountRatesMemberifrs-full:ForeignCountriesMember2021-03-310001395064ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMemberifrs-full:ForeignCountriesMember2021-03-310001395064ifrs-full:PlanAssetsMember2019-03-310001395064ifrs-full:PlanAssetsMember2020-03-310001395064ifrs-full:PlanAssetsMember2019-04-012020-03-310001395064ifrs-full:PlanAssetsMember2020-04-012021-03-310001395064ifrs-full:PlanAssetsMember2021-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:CountryOfDomicileMember2020-03-310001395064ifrs-full:Level2And3OfFairValueHierarchyMemberifrs-full:CountryOfDomicileMember2020-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:CountryOfDomicileMember2021-03-310001395064ifrs-full:Level2And3OfFairValueHierarchyMemberifrs-full:CountryOfDomicileMember2021-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:ForeignCountriesMember2020-03-310001395064ifrs-full:Level2And3OfFairValueHierarchyMemberifrs-full:ForeignCountriesMember2020-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:ForeignCountriesMember2021-03-310001395064ifrs-full:Level2And3OfFairValueHierarchyMemberifrs-full:ForeignCountriesMember2021-03-310001395064ifrs-full:Level2And3OfFairValueHierarchyMember2020-03-310001395064ifrs-full:Level2And3OfFairValueHierarchyMember2021-03-310001395064ifrs-full:EffectOfAssetCeilingMemberifrs-full:CountryOfDomicileMember2019-03-310001395064ifrs-full:EffectOfAssetCeilingMemberifrs-full:CountryOfDomicileMember2020-03-310001395064ifrs-full:EffectOfAssetCeilingMemberifrs-full:CountryOfDomicileMember2020-04-012021-03-310001395064ifrs-full:EffectOfAssetCeilingMemberifrs-full:CountryOfDomicileMember2019-04-012020-03-310001395064ifrs-full:LegalProceedingsProvisionMemberifrs-full:PreviouslyStatedMember2019-03-310001395064ifrs-full:PreviouslyStatedMemberifrs-full:RestructuringProvisionMember2019-03-310001395064ifrs-full:RefundsProvisionMemberifrs-full:PreviouslyStatedMember2019-03-310001395064ifrs-full:MiscellaneousOtherProvisionsMemberifrs-full:PreviouslyStatedMember2019-03-310001395064ifrs-full:PreviouslyStatedMember2019-03-310001395064ifrs-full:LegalProceedingsProvisionMemberifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember2019-03-310001395064ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMemberifrs-full:RestructuringProvisionMember2019-03-310001395064ifrs-full:RefundsProvisionMemberifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember2019-03-310001395064ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMemberifrs-full:MiscellaneousOtherProvisionsMember2019-03-310001395064ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember2019-03-310001395064ifrs-full:LegalProceedingsProvisionMember2019-03-310001395064ifrs-full:RestructuringProvisionMember2019-03-310001395064ifrs-full:RefundsProvisionMember2019-03-310001395064ifrs-full:MiscellaneousOtherProvisionsMember2019-03-310001395064ifrs-full:LegalProceedingsProvisionMember2019-04-012020-03-310001395064ifrs-full:RestructuringProvisionMember2019-04-012020-03-310001395064ifrs-full:RefundsProvisionMember2019-04-012020-03-310001395064ifrs-full:MiscellaneousOtherProvisionsMember2019-04-012020-03-310001395064ifrs-full:LegalProceedingsProvisionMember2020-03-310001395064ifrs-full:RestructuringProvisionMember2020-03-310001395064ifrs-full:RefundsProvisionMember2020-03-310001395064ifrs-full:MiscellaneousOtherProvisionsMember2020-03-310001395064ifrs-full:RestructuringProvisionMember2020-04-012021-03-310001395064ifrs-full:RefundsProvisionMember2020-04-012021-03-310001395064ifrs-full:MiscellaneousOtherProvisionsMember2020-04-012021-03-310001395064ifrs-full:LegalProceedingsProvisionMember2021-03-310001395064ifrs-full:RestructuringProvisionMember2021-03-310001395064ifrs-full:RefundsProvisionMember2021-03-310001395064ifrs-full:MiscellaneousOtherProvisionsMember2021-03-310001395064tak:EmployeeSeveranceMember2018-04-012019-03-310001395064tak:EmployeeSeveranceMember2019-04-012020-03-310001395064tak:EmployeeSeveranceMember2020-04-012021-03-310001395064tak:ConsultingFeesMember2018-04-012019-03-310001395064tak:ConsultingFeesMember2019-04-012020-03-310001395064tak:ConsultingFeesMember2020-04-012021-03-310001395064tak:OtherRestructuringMember2018-04-012019-03-310001395064tak:OtherRestructuringMember2019-04-012020-03-310001395064tak:OtherRestructuringMember2020-04-012021-03-310001395064tak:PersonnelCostsMember2018-04-012019-03-310001395064tak:PersonnelCostsMember2019-04-012020-03-310001395064tak:PersonnelCostsMember2020-04-012021-03-310001395064tak:EmployeeStockOwnershipPlanTrustAndBoardIncentivePlanTrustMember2019-03-310001395064tak:EmployeeStockOwnershipPlanTrustAndBoardIncentivePlanTrustMember2020-03-310001395064tak:EmployeeStockOwnershipPlanTrustAndBoardIncentivePlanTrustMember2021-03-310001395064tak:EmployeeStockOwnershipPlanTrustAndBoardIncentivePlanTrustMember2019-04-012020-03-310001395064tak:EmployeeStockOwnershipPlanTrustAndBoardIncentivePlanTrustMember2020-04-012021-03-310001395064tak:MasterTrustBankOfJapanLtdMemberifrs-full:IssuedCapitalMember2019-04-012020-03-310001395064ifrs-full:SharePremiumMembertak:MasterTrustBankOfJapanLtdMember2019-04-012020-03-310001395064tak:MasterTrustBankOfJapanLtdMember2019-04-012020-03-3100013950642017-04-012017-06-3000013950642017-10-012017-12-3100013950642018-04-012018-06-3000013950642018-10-012018-12-3100013950642019-04-012019-06-3000013950642019-10-012019-12-3100013950642020-04-012020-06-300001395064ifrs-full:EquityInvestmentsMemberifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember2020-03-310001395064ifrs-full:FinancialAssetsAtFairValueMemberifrs-full:EquityInvestmentsMember2020-03-310001395064ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:DerivativesMember2020-03-310001395064ifrs-full:DerivativesMembertak:FinancialAssetsAtFairValueThroughDerivativeHedgingInstrumentsMember2020-03-310001395064ifrs-full:FinancialAssetsAtFairValueMemberifrs-full:DerivativesMember2020-03-310001395064tak:ConvertibleNotesMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:ConvertibleNotesMemberifrs-full:FinancialAssetsAtFairValueMember2020-03-310001395064ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:DebtSecuritiesMember2020-03-310001395064ifrs-full:FinancialAssetsAtFairValueMemberifrs-full:DebtSecuritiesMember2020-03-310001395064ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMembertak:ContingentConsiderationAssetMember2020-03-310001395064ifrs-full:FinancialAssetsAtFairValueMembertak:ContingentConsiderationAssetMember2020-03-310001395064ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember2020-03-310001395064ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:FinancialAssetsAtFairValueThroughDerivativeHedgingInstrumentsMember2020-03-310001395064ifrs-full:FinancialAssetsAtFairValueMember2020-03-310001395064tak:OtherFinancialAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostMember2020-03-310001395064ifrs-full:FinancialAssetsAtAmortisedCostMembertak:TradeAndOtherReceivablesMember2020-03-310001395064ifrs-full:FinancialAssetsAtAmortisedCostMembertak:CashAndCashEquivalentsMember2020-03-310001395064ifrs-full:FinancialAssetsAtAmortisedCostMember2020-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:DerivativesMember2020-03-310001395064tak:FinancialLiabilitiesatFairValueThroughDerivativeHedgingInstrumentsMemberifrs-full:CashFlowHedgesMemberifrs-full:DerivativesMember2020-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueMemberifrs-full:DerivativesMember2020-03-310001395064tak:ContingentConsiderationLiabilityMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:ContingentConsiderationLiabilityMemberifrs-full:FinancialLiabilitiesAtFairValueMember2020-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembertak:OtherFinancialLiabilitiesMember2020-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueMembertak:OtherFinancialLiabilitiesMember2020-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:FinancialLiabilitiesatFairValueThroughDerivativeHedgingInstrumentsMemberifrs-full:CashFlowHedgesMember2020-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueMember2020-03-310001395064ifrs-full:CashFlowHedgesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMembertak:FinanceLeaseLiabilityMember2020-03-310001395064ifrs-full:FinancialLiabilitiesAtAmortisedCostMembertak:FinanceLeaseLiabilityMember2020-03-310001395064tak:OtherFinancialLiabilitiesMemberifrs-full:CashFlowHedgesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2020-03-310001395064tak:OtherFinancialLiabilitiesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2020-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:CashFlowHedgesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2020-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2020-03-310001395064tak:BondsAndLoansMemberifrs-full:CashFlowHedgesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2020-03-310001395064tak:BondsAndLoansMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2020-03-310001395064ifrs-full:FinancialLiabilitiesAtAmortisedCostMember2020-03-310001395064ifrs-full:EquityInvestmentsMemberifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember2021-03-310001395064ifrs-full:FinancialAssetsAtFairValueMemberifrs-full:EquityInvestmentsMember2021-03-310001395064ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:DerivativesMember2021-03-310001395064ifrs-full:DerivativesMembertak:FinancialAssetsAtFairValueThroughDerivativeHedgingInstrumentsMember2021-03-310001395064ifrs-full:FinancialAssetsAtFairValueMemberifrs-full:DerivativesMember2021-03-310001395064tak:ConvertibleNotesMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:ConvertibleNotesMemberifrs-full:FinancialAssetsAtFairValueMember2021-03-310001395064ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:DebtSecuritiesMember2021-03-310001395064ifrs-full:FinancialAssetsAtFairValueMemberifrs-full:DebtSecuritiesMember2021-03-310001395064ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMembertak:ContingentConsiderationAssetMember2021-03-310001395064ifrs-full:FinancialAssetsAtFairValueMembertak:ContingentConsiderationAssetMember2021-03-310001395064ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember2021-03-310001395064ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:FinancialAssetsAtFairValueThroughDerivativeHedgingInstrumentsMember2021-03-310001395064ifrs-full:FinancialAssetsAtFairValueMember2021-03-310001395064tak:OtherFinancialAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostMember2021-03-310001395064ifrs-full:FinancialAssetsAtAmortisedCostMembertak:TradeAndOtherReceivablesMember2021-03-310001395064ifrs-full:FinancialAssetsAtAmortisedCostMembertak:CashAndCashEquivalentsMember2021-03-310001395064ifrs-full:FinancialAssetsAtAmortisedCostMember2021-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:DerivativesMember2021-03-310001395064tak:FinancialLiabilitiesatFairValueThroughDerivativeHedgingInstrumentsMemberifrs-full:CashFlowHedgesMemberifrs-full:DerivativesMember2021-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueMemberifrs-full:DerivativesMember2021-03-310001395064tak:ContingentConsiderationLiabilityMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:ContingentConsiderationLiabilityMemberifrs-full:FinancialLiabilitiesAtFairValueMember2021-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembertak:OtherFinancialLiabilitiesMember2021-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueMembertak:OtherFinancialLiabilitiesMember2021-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:FinancialLiabilitiesatFairValueThroughDerivativeHedgingInstrumentsMemberifrs-full:CashFlowHedgesMember2021-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueMember2021-03-310001395064ifrs-full:CashFlowHedgesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMembertak:FinanceLeaseLiabilityMember2021-03-310001395064ifrs-full:FinancialLiabilitiesAtAmortisedCostMembertak:FinanceLeaseLiabilityMember2021-03-310001395064tak:OtherFinancialLiabilitiesMemberifrs-full:CashFlowHedgesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-03-310001395064tak:OtherFinancialLiabilitiesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:CashFlowHedgesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-03-310001395064tak:BondsAndLoansMemberifrs-full:CashFlowHedgesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-03-310001395064tak:BondsAndLoansMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-03-310001395064ifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:DerivativesMember2020-03-310001395064ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:DerivativesMember2020-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:DerivativesMember2020-03-310001395064ifrs-full:AtFairValueMemberifrs-full:DerivativesMember2020-03-310001395064tak:ConvertibleNotesMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMember2020-03-310001395064tak:ConvertibleNotesMemberifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMember2020-03-310001395064tak:ConvertibleNotesMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2020-03-310001395064tak:ConvertibleNotesMemberifrs-full:AtFairValueMember2020-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:DebtSecuritiesMember2020-03-310001395064ifrs-full:AtFairValueMemberifrs-full:DebtSecuritiesMemberifrs-full:Level2OfFairValueHierarchyMember2020-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:DebtSecuritiesMember2020-03-310001395064ifrs-full:DebtSecuritiesMemberifrs-full:AtFairValueMember2020-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMembertak:ContingentConsiderationAssetMember2020-03-310001395064ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMembertak:ContingentConsiderationAssetMember2020-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMembertak:ContingentConsiderationAssetMember2020-03-310001395064ifrs-full:AtFairValueMembertak:ContingentConsiderationAssetMember2020-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMemberifrs-full:DerivativesMember2020-03-310001395064ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:CashFlowHedgesMemberifrs-full:DerivativesMember2020-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMemberifrs-full:DerivativesMember2020-03-310001395064ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMemberifrs-full:DerivativesMember2020-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:EquityInvestmentsMember2020-03-310001395064ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:EquityInvestmentsMember2020-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:EquityInvestmentsMember2020-03-310001395064ifrs-full:AtFairValueMemberifrs-full:EquityInvestmentsMember2020-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMember2020-03-310001395064ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMember2020-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2020-03-310001395064ifrs-full:AtFairValueMember2020-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:DerivativesMemberifrs-full:AtFairValueMember2020-03-310001395064ifrs-full:DerivativesMemberifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMember2020-03-310001395064ifrs-full:DerivativesMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2020-03-310001395064ifrs-full:DerivativesMemberifrs-full:AtFairValueMember2020-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMembertak:ContingentConsiderationLiabilityMember2020-03-310001395064ifrs-full:AtFairValueMembertak:ContingentConsiderationLiabilityMemberifrs-full:Level2OfFairValueHierarchyMember2020-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMembertak:ContingentConsiderationLiabilityMember2020-03-310001395064ifrs-full:AtFairValueMembertak:ContingentConsiderationLiabilityMember2020-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMembertak:OtherFinancialLiabilitiesMember2020-03-310001395064ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMembertak:OtherFinancialLiabilitiesMember2020-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMembertak:OtherFinancialLiabilitiesMember2020-03-310001395064ifrs-full:AtFairValueMembertak:OtherFinancialLiabilitiesMember2020-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:DerivativesMemberifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMember2020-03-310001395064ifrs-full:DerivativesMemberifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:CashFlowHedgesMember2020-03-310001395064ifrs-full:DerivativesMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMember2020-03-310001395064ifrs-full:DerivativesMemberifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMember2020-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:DerivativesMember2021-03-310001395064ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:DerivativesMember2021-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:DerivativesMember2021-03-310001395064ifrs-full:AtFairValueMemberifrs-full:DerivativesMember2021-03-310001395064tak:ConvertibleNotesMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMember2021-03-310001395064tak:ConvertibleNotesMemberifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMember2021-03-310001395064tak:ConvertibleNotesMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2021-03-310001395064tak:ConvertibleNotesMemberifrs-full:AtFairValueMember2021-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:DebtSecuritiesMember2021-03-310001395064ifrs-full:AtFairValueMemberifrs-full:DebtSecuritiesMemberifrs-full:Level2OfFairValueHierarchyMember2021-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:DebtSecuritiesMember2021-03-310001395064ifrs-full:DebtSecuritiesMemberifrs-full:AtFairValueMember2021-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMembertak:ContingentConsiderationAssetMember2021-03-310001395064ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMembertak:ContingentConsiderationAssetMember2021-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMembertak:ContingentConsiderationAssetMember2021-03-310001395064ifrs-full:AtFairValueMembertak:ContingentConsiderationAssetMember2021-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMemberifrs-full:DerivativesMember2021-03-310001395064ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:CashFlowHedgesMemberifrs-full:DerivativesMember2021-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMemberifrs-full:DerivativesMember2021-03-310001395064ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMemberifrs-full:DerivativesMember2021-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:EquityInvestmentsMember2021-03-310001395064ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:EquityInvestmentsMember2021-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:EquityInvestmentsMember2021-03-310001395064ifrs-full:AtFairValueMemberifrs-full:EquityInvestmentsMember2021-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMember2021-03-310001395064ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMember2021-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2021-03-310001395064ifrs-full:AtFairValueMember2021-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:DerivativesMemberifrs-full:AtFairValueMember2021-03-310001395064ifrs-full:DerivativesMemberifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMember2021-03-310001395064ifrs-full:DerivativesMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2021-03-310001395064ifrs-full:DerivativesMemberifrs-full:AtFairValueMember2021-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMembertak:ContingentConsiderationLiabilityMember2021-03-310001395064ifrs-full:AtFairValueMembertak:ContingentConsiderationLiabilityMemberifrs-full:Level2OfFairValueHierarchyMember2021-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMembertak:ContingentConsiderationLiabilityMember2021-03-310001395064ifrs-full:AtFairValueMembertak:ContingentConsiderationLiabilityMember2021-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMembertak:OtherFinancialLiabilitiesMember2021-03-310001395064ifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMembertak:OtherFinancialLiabilitiesMember2021-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMembertak:OtherFinancialLiabilitiesMember2021-03-310001395064ifrs-full:AtFairValueMembertak:OtherFinancialLiabilitiesMember2021-03-310001395064ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:DerivativesMemberifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMember2021-03-310001395064ifrs-full:DerivativesMemberifrs-full:AtFairValueMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:CashFlowHedgesMember2021-03-310001395064ifrs-full:DerivativesMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMember2021-03-310001395064ifrs-full:DerivativesMemberifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMember2021-03-310001395064srt:MinimumMember2020-04-012021-03-310001395064srt:MaximumMember2020-04-012021-03-310001395064ifrs-full:Level3OfFairValueHierarchyMembertak:ContingentConsiderationAssetMember2019-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:EquityInvestmentsMember2019-03-310001395064ifrs-full:Level3OfFairValueHierarchyMembertak:ContingentConsiderationAssetMember2020-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:EquityInvestmentsMember2020-03-310001395064ifrs-full:Level3OfFairValueHierarchyMembertak:ContingentConsiderationAssetMember2019-04-012020-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:EquityInvestmentsMember2019-04-012020-03-310001395064ifrs-full:Level3OfFairValueHierarchyMembertak:ContingentConsiderationAssetMember2020-04-012021-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:EquityInvestmentsMember2020-04-012021-03-310001395064ifrs-full:Level3OfFairValueHierarchyMembertak:ContingentConsiderationAssetMember2021-03-310001395064ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:EquityInvestmentsMember2021-03-310001395064tak:XiidraMember2020-04-012021-03-310001395064tak:ShireMember2021-03-310001395064ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2020-03-310001395064ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2021-03-310001395064ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2020-03-310001395064ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2021-03-310001395064tak:ShireMember2019-04-012020-03-310001395064tak:ShireMember2020-04-012021-03-310001395064tak:BondsMember2020-03-310001395064tak:BondsMember2021-03-310001395064tak:LongTermLoansMemberifrs-full:LongtermBorrowingsMember2020-03-310001395064tak:LongTermLoansMemberifrs-full:LongtermBorrowingsMember2021-03-310001395064tak:ForeignCurrencyDenominatedLoansMember2020-03-310001395064tak:ForeignCurrencyDenominatedLoansMember2021-03-310001395064tak:ForeignCurrencyDenominatedBondsMember2020-03-310001395064tak:ForeignCurrencyDenominatedBondsMember2021-03-310001395064currency:EURtak:ForwardExchangeContractSellingMemberifrs-full:NotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMember2020-03-310001395064currency:EURtak:ForwardExchangeContractSellingMemberifrs-full:LaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMember2020-03-310001395064currency:EURtak:ForwardExchangeContractSellingMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMember2020-03-310001395064tak:ForwardExchangeContractSellingMembercurrency:USDifrs-full:NotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMember2020-03-310001395064tak:ForwardExchangeContractSellingMemberifrs-full:LaterThanOneYearMembercurrency:USDifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMember2020-03-310001395064tak:ForwardExchangeContractSellingMembercurrency:USDifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMember2020-03-310001395064currency:EURifrs-full:NotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMember2020-03-310001395064currency:EURifrs-full:LaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMember2020-03-310001395064currency:EURifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMember2020-03-310001395064currency:USDifrs-full:NotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMember2020-03-310001395064ifrs-full:LaterThanOneYearMembercurrency:USDifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMember2020-03-310001395064currency:USDifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMember2020-03-310001395064currency:USDifrs-full:NotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMemberifrs-full:CurrencySwapContractMember2020-03-310001395064ifrs-full:LaterThanOneYearMembercurrency:USDifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMemberifrs-full:CurrencySwapContractMember2020-03-310001395064currency:USDifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMemberifrs-full:CurrencySwapContractMember2020-03-310001395064currency:RUBifrs-full:NotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:CurrencyCollarOptionMember2020-03-310001395064currency:RUBifrs-full:LaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:CurrencyCollarOptionMember2020-03-310001395064currency:RUBifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:CurrencyCollarOptionMember2020-03-310001395064currency:BRLifrs-full:NotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:CurrencyCollarOptionMember2020-03-310001395064currency:BRLifrs-full:LaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:CurrencyCollarOptionMember2020-03-310001395064currency:BRLifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:CurrencyCollarOptionMember2020-03-310001395064ifrs-full:NotLaterThanOneYearMembercurrency:INRifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:CurrencyCollarOptionMember2020-03-310001395064ifrs-full:LaterThanOneYearMembercurrency:INRifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:CurrencyCollarOptionMember2020-03-310001395064currency:INRifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:CurrencyCollarOptionMember2020-03-310001395064currency:EURtak:ForwardExchangeContractSellingMemberifrs-full:NotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMember2021-03-310001395064currency:EURtak:ForwardExchangeContractSellingMemberifrs-full:LaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMember2021-03-310001395064currency:EURtak:ForwardExchangeContractSellingMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMember2021-03-310001395064tak:ForwardExchangeContractSellingMembercurrency:USDifrs-full:NotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMember2021-03-310001395064tak:ForwardExchangeContractSellingMemberifrs-full:LaterThanOneYearMembercurrency:USDifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMember2021-03-310001395064tak:ForwardExchangeContractSellingMembercurrency:USDifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMember2021-03-310001395064currency:EURifrs-full:NotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMember2021-03-310001395064currency:EURifrs-full:LaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMember2021-03-310001395064currency:EURifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMember2021-03-310001395064currency:USDifrs-full:NotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMember2021-03-310001395064ifrs-full:LaterThanOneYearMembercurrency:USDifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMember2021-03-310001395064currency:USDifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMember2021-03-310001395064ifrs-full:NotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMembertak:OtherCurrenciesMember2021-03-310001395064ifrs-full:LaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMembertak:OtherCurrenciesMember2021-03-310001395064ifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMembertak:ForwardExchangeContractBuyingMembertak:OtherCurrenciesMember2021-03-310001395064currency:USDifrs-full:NotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMemberifrs-full:CurrencySwapContractMember2021-03-310001395064ifrs-full:LaterThanOneYearMembercurrency:USDifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMemberifrs-full:CurrencySwapContractMember2021-03-310001395064currency:USDifrs-full:CurrencyRiskMemberifrs-full:CashFlowHedgesMemberifrs-full:CurrencySwapContractMember2021-03-310001395064ifrs-full:InterestRateRiskMembertak:InterestRateAndCurrencySwapMemberifrs-full:CashFlowHedgesMember2020-03-310001395064ifrs-full:LaterThanOneYearMemberifrs-full:InterestRateRiskMembertak:InterestRateAndCurrencySwapMemberifrs-full:CashFlowHedgesMember2020-03-310001395064ifrs-full:InterestRateRiskMembertak:InterestRateAndCurrencySwapMemberifrs-full:CashFlowHedgesMember2021-03-310001395064ifrs-full:LaterThanOneYearMemberifrs-full:InterestRateRiskMembertak:InterestRateAndCurrencySwapMemberifrs-full:CashFlowHedgesMember2021-03-310001395064ifrs-full:InterestRateRiskMembertak:InterestRateAndCurrencySwapMemberifrs-full:CashFlowHedgesMember2019-04-012020-03-310001395064ifrs-full:InterestRateRiskMembertak:InterestRateAndCurrencySwapMemberifrs-full:CashFlowHedgesMember2020-04-012021-03-310001395064ifrs-full:InterestRateRiskMemberifrs-full:CashFlowHedgesMemberifrs-full:InterestRateSwapContractMember2020-03-310001395064currency:JPYifrs-full:InterestRateRiskMemberifrs-full:CashFlowHedgesMemberifrs-full:InterestRateSwapContractMember2020-03-310001395064ifrs-full:InterestRateRiskMembercurrency:USDifrs-full:CashFlowHedgesMemberifrs-full:InterestRateSwapContractMember2020-03-310001395064ifrs-full:InterestRateRiskMemberifrs-full:ForwardContractMemberifrs-full:CashFlowHedgesMember2021-03-310001395064ifrs-full:InterestRateRiskMemberifrs-full:ForwardContractMembercurrency:USDifrs-full:CashFlowHedgesMember2020-03-310001395064currency:EURifrs-full:InterestRateRiskMemberifrs-full:ForwardContractMemberifrs-full:CashFlowHedgesMember2020-03-310001395064tak:InterestRateAndCurrencySwapMemberifrs-full:CashFlowHedgesMembertak:CurrencyAndInterestRateRiskMember2020-03-310001395064tak:InterestRateAndCurrencySwapMembercurrency:USDifrs-full:CashFlowHedgesMembertak:CurrencyAndInterestRateRiskMember2020-03-31iso4217:JPYiso4217:USD0001395064tak:InterestRateAndCurrencySwapMemberifrs-full:CashFlowHedgesMembertak:CurrencyAndInterestRateRiskMember2019-04-012020-03-310001395064ifrs-full:HedgesOfNetInvestmentInForeignOperationsMembertak:ForeignCurrencyDenominatedBondsAndLoansMembertak:CurrencyAndInterestRateRiskMember2020-03-310001395064ifrs-full:HedgesOfNetInvestmentInForeignOperationsMembercurrency:USDtak:ForeignCurrencyDenominatedBondsAndLoansMembertak:CurrencyAndInterestRateRiskMember2020-03-310001395064currency:EURifrs-full:HedgesOfNetInvestmentInForeignOperationsMembertak:ForeignCurrencyDenominatedBondsAndLoansMembertak:CurrencyAndInterestRateRiskMember2020-03-310001395064ifrs-full:InterestRateSwapContractMember2020-03-310001395064ifrs-full:ForwardContractMember2020-03-310001395064tak:InterestRateAndCurrencySwapMember2020-03-310001395064ifrs-full:CurrencySwapContractMember2020-03-310001395064tak:ForeignCurrencyDenominatedBondsAndLoansMember2020-03-310001395064ifrs-full:InterestRateSwapContractMember2019-04-012020-03-310001395064tak:HedgeGainLossMemberifrs-full:InterestRateSwapContractMember2019-04-012020-03-310001395064ifrs-full:ForwardContractMember2019-04-012020-03-310001395064ifrs-full:ForwardContractMembertak:HedgeGainLossMember2019-04-012020-03-310001395064tak:InterestRateAndCurrencySwapMember2019-04-012020-03-310001395064tak:HedgeGainLossMember2019-04-012020-03-310001395064tak:HedgeCostMember2019-04-012020-03-310001395064ifrs-full:CurrencySwapContractMember2019-04-012020-03-310001395064tak:ForeignCurrencyDenominatedBondsAndLoansMember2019-04-012020-03-310001395064ifrs-full:InterestRateRiskMemberifrs-full:CashFlowHedgesMemberifrs-full:InterestRateSwapContractMember2021-03-310001395064currency:JPYifrs-full:InterestRateRiskMemberifrs-full:CashFlowHedgesMemberifrs-full:InterestRateSwapContractMember2021-03-310001395064tak:InterestRateAndCurrencySwapMemberifrs-full:CashFlowHedgesMembertak:CurrencyAndInterestRateRiskMember2021-03-310001395064tak:InterestRateAndCurrencySwapMembercurrency:USDifrs-full:CashFlowHedgesMembertak:CurrencyAndInterestRateRiskMember2021-03-310001395064tak:InterestRateAndCurrencySwapMembercurrency:USDsrt:MinimumMemberifrs-full:CashFlowHedgesMembertak:CurrencyAndInterestRateRiskMember2020-04-012021-03-310001395064tak:InterestRateAndCurrencySwapMembercurrency:USDsrt:MaximumMemberifrs-full:CashFlowHedgesMembertak:CurrencyAndInterestRateRiskMember2021-03-310001395064ifrs-full:HedgesOfNetInvestmentInForeignOperationsMembertak:ForeignCurrencyDenominatedBondsAndLoansMembertak:CurrencyAndInterestRateRiskMember2021-03-310001395064ifrs-full:HedgesOfNetInvestmentInForeignOperationsMembercurrency:USDtak:ForeignCurrencyDenominatedBondsAndLoansMembertak:CurrencyAndInterestRateRiskMember2021-03-310001395064currency:EURifrs-full:HedgesOfNetInvestmentInForeignOperationsMembertak:ForeignCurrencyDenominatedBondsAndLoansMembertak:CurrencyAndInterestRateRiskMember2021-03-310001395064tak:ForwardExchangeContractsMemberifrs-full:HedgesOfNetInvestmentInForeignOperationsMembertak:CurrencyAndInterestRateRiskMember2021-03-310001395064tak:ForwardExchangeContractsMemberifrs-full:HedgesOfNetInvestmentInForeignOperationsMembercurrency:USDtak:CurrencyAndInterestRateRiskMember2021-03-310001395064currency:EURtak:ForwardExchangeContractsMemberifrs-full:HedgesOfNetInvestmentInForeignOperationsMembertak:CurrencyAndInterestRateRiskMember2021-03-310001395064ifrs-full:InterestRateSwapContractMember2021-03-310001395064ifrs-full:ForwardContractMember2021-03-310001395064tak:InterestRateAndCurrencySwapMember2021-03-310001395064ifrs-full:CurrencySwapContractMember2021-03-310001395064tak:ForeignCurrencyDenominatedBondsAndLoansMember2021-03-310001395064tak:ForwardExchangeContractsMember2021-03-310001395064ifrs-full:InterestRateSwapContractMember2020-04-012021-03-310001395064tak:HedgeGainLossMemberifrs-full:InterestRateSwapContractMember2020-04-012021-03-310001395064ifrs-full:ForwardContractMember2020-04-012021-03-310001395064ifrs-full:ForwardContractMembertak:HedgeGainLossMember2020-04-012021-03-310001395064tak:InterestRateAndCurrencySwapMember2020-04-012021-03-310001395064tak:HedgeGainLossMember2020-04-012021-03-310001395064tak:HedgeCostMember2020-04-012021-03-310001395064tak:ForeignCurrencyDenominatedBondsAndLoansMember2020-04-012021-03-310001395064tak:ForwardExchangeContractsMember2020-04-012021-03-310001395064ifrs-full:CurrentMember2020-03-310001395064ifrs-full:NotLaterThanOneMonthMember2020-03-310001395064ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2020-03-310001395064ifrs-full:NotLaterThanThreeMonthsMember2020-03-310001395064ifrs-full:LaterThanThreeMonthsAndNotLaterThanOneYearMember2020-03-310001395064ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember2020-03-310001395064ifrs-full:CurrentMember2021-03-310001395064ifrs-full:NotLaterThanOneMonthMember2021-03-310001395064ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2021-03-310001395064ifrs-full:NotLaterThanThreeMonthsMember2021-03-310001395064ifrs-full:LaterThanThreeMonthsAndNotLaterThanOneYearMember2021-03-310001395064ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember2021-03-310001395064ifrs-full:TradeReceivablesMembertak:BadDebtProvisionCalculatedBySimplifiedApproachMember2019-03-310001395064ifrs-full:TradeReceivablesMembertak:BadDebtProvisionRecognizedtoCreditImpairedFinancialAssetsMember2019-03-310001395064ifrs-full:TradeReceivablesMember2019-03-310001395064ifrs-full:TradeReceivablesMembertak:BadDebtProvisionCalculatedBySimplifiedApproachMember2019-04-012020-03-310001395064ifrs-full:TradeReceivablesMembertak:BadDebtProvisionRecognizedtoCreditImpairedFinancialAssetsMember2019-04-012020-03-310001395064ifrs-full:TradeReceivablesMember2019-04-012020-03-310001395064ifrs-full:TradeReceivablesMembertak:BadDebtProvisionCalculatedBySimplifiedApproachMember2020-03-310001395064ifrs-full:TradeReceivablesMembertak:BadDebtProvisionRecognizedtoCreditImpairedFinancialAssetsMember2020-03-310001395064ifrs-full:TradeReceivablesMember2020-03-310001395064ifrs-full:TradeReceivablesMembertak:BadDebtProvisionCalculatedBySimplifiedApproachMember2020-04-012021-03-310001395064ifrs-full:TradeReceivablesMembertak:BadDebtProvisionRecognizedtoCreditImpairedFinancialAssetsMember2020-04-012021-03-310001395064ifrs-full:TradeReceivablesMember2020-04-012021-03-310001395064ifrs-full:TradeReceivablesMembertak:BadDebtProvisionCalculatedBySimplifiedApproachMember2021-03-310001395064ifrs-full:TradeReceivablesMembertak:BadDebtProvisionRecognizedtoCreditImpairedFinancialAssetsMember2021-03-310001395064ifrs-full:TradeReceivablesMember2021-03-310001395064tak:BondsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:BondsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:NotLaterThanOneYearMember2020-03-310001395064tak:BondsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2020-03-310001395064ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembertak:BondsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:BondsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2020-03-310001395064ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembertak:BondsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064ifrs-full:LaterThanFiveYearsMembertak:BondsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:LongTermLoansMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:LongTermLoansMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:NotLaterThanOneYearMember2020-03-310001395064tak:LongTermLoansMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2020-03-310001395064tak:LongTermLoansMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:LongTermLoansMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2020-03-310001395064tak:LongTermLoansMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:LongTermLoansMemberifrs-full:LaterThanFiveYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:NotLaterThanOneYearMember2020-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2020-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2020-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064ifrs-full:LaterThanFiveYearsMembertak:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembertak:FinanceLeaseLiabilityMember2020-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:NotLaterThanOneYearMembertak:FinanceLeaseLiabilityMember2020-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMembertak:FinanceLeaseLiabilityMember2020-03-310001395064ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembertak:FinanceLeaseLiabilityMember2020-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMembertak:FinanceLeaseLiabilityMember2020-03-310001395064ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembertak:FinanceLeaseLiabilityMember2020-03-310001395064ifrs-full:LaterThanFiveYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembertak:FinanceLeaseLiabilityMember2020-03-310001395064tak:DerivativeLiabilitiesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:DerivativeLiabilitiesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:NotLaterThanOneYearMember2020-03-310001395064tak:DerivativeLiabilitiesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2020-03-310001395064tak:DerivativeLiabilitiesMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:DerivativeLiabilitiesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2020-03-310001395064tak:DerivativeLiabilitiesMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:DerivativeLiabilitiesMemberifrs-full:LaterThanFiveYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:DerivativeAssetsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:DerivativeAssetsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:NotLaterThanOneYearMember2020-03-310001395064tak:DerivativeAssetsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2020-03-310001395064ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembertak:DerivativeAssetsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:DerivativeAssetsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2020-03-310001395064ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembertak:DerivativeAssetsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064ifrs-full:LaterThanFiveYearsMembertak:DerivativeAssetsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2020-03-310001395064tak:BondsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:BondsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:NotLaterThanOneYearMember2021-03-310001395064tak:BondsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2021-03-310001395064ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembertak:BondsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:BondsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2021-03-310001395064ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembertak:BondsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064ifrs-full:LaterThanFiveYearsMembertak:BondsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:LongTermLoansMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:LongTermLoansMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:NotLaterThanOneYearMember2021-03-310001395064tak:LongTermLoansMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2021-03-310001395064tak:LongTermLoansMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:LongTermLoansMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2021-03-310001395064tak:LongTermLoansMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:LongTermLoansMemberifrs-full:LaterThanFiveYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:NotLaterThanOneYearMember2021-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2021-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2021-03-310001395064tak:TradeAndOtherPayablesMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064ifrs-full:LaterThanFiveYearsMembertak:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembertak:FinanceLeaseLiabilityMember2021-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:NotLaterThanOneYearMembertak:FinanceLeaseLiabilityMember2021-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMembertak:FinanceLeaseLiabilityMember2021-03-310001395064ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembertak:FinanceLeaseLiabilityMember2021-03-310001395064ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMembertak:FinanceLeaseLiabilityMember2021-03-310001395064ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembertak:FinanceLeaseLiabilityMember2021-03-310001395064ifrs-full:LaterThanFiveYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembertak:FinanceLeaseLiabilityMember2021-03-310001395064tak:DerivativeLiabilitiesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:DerivativeLiabilitiesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:NotLaterThanOneYearMember2021-03-310001395064tak:DerivativeLiabilitiesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2021-03-310001395064tak:DerivativeLiabilitiesMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:DerivativeLiabilitiesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2021-03-310001395064tak:DerivativeLiabilitiesMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:DerivativeLiabilitiesMemberifrs-full:LaterThanFiveYearsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:DerivativeAssetsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:DerivativeAssetsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:NotLaterThanOneYearMember2021-03-310001395064tak:DerivativeAssetsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2021-03-310001395064ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembertak:DerivativeAssetsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:DerivativeAssetsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2021-03-310001395064ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembertak:DerivativeAssetsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064ifrs-full:LaterThanFiveYearsMembertak:DerivativeAssetsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-03-310001395064tak:USDUnsecuredSeniorNotesMemberifrs-full:NotLaterThanOneYearMember2021-03-310001395064ifrs-full:NotLaterThanOneYearMembertak:JBICLoanMember2021-03-310001395064tak:JBICLoanMember2021-03-310001395064tak:BondsMember2019-03-310001395064tak:LongTermLoansMember2019-03-310001395064ifrs-full:ShorttermBorrowingsMember2019-03-310001395064tak:FinanceLeaseLiabilityMember2019-03-310001395064tak:DerivativeAssetsMember2019-03-310001395064tak:DerivativeLiabilitiesMember2019-03-310001395064tak:BondsMember2019-04-012020-03-310001395064ifrs-full:ShorttermBorrowingsMember2019-04-012020-03-310001395064tak:LongTermLoansMember2019-04-012020-03-310001395064tak:FinanceLeaseLiabilityMember2019-04-012020-03-310001395064tak:DerivativeAssetsMember2019-04-012020-03-310001395064tak:DerivativeLiabilitiesMember2019-04-012020-03-310001395064tak:BondsMember2020-03-310001395064tak:LongTermLoansMember2020-03-310001395064ifrs-full:ShorttermBorrowingsMember2020-03-310001395064tak:FinanceLeaseLiabilityMember2020-03-310001395064tak:DerivativeAssetsMember2020-03-310001395064tak:DerivativeLiabilitiesMember2020-03-310001395064tak:BondsMember2020-04-012021-03-310001395064ifrs-full:ShorttermBorrowingsMember2020-04-012021-03-310001395064tak:DerivativeAssetsMember2020-04-012021-03-310001395064tak:LongTermLoansMember2020-04-012021-03-310001395064tak:FinanceLeaseLiabilityMember2020-04-012021-03-310001395064tak:DerivativeLiabilitiesMember2020-04-012021-03-310001395064tak:BondsMember2021-03-310001395064tak:LongTermLoansMember2021-03-310001395064ifrs-full:ShorttermBorrowingsMember2021-03-310001395064tak:FinanceLeaseLiabilityMember2021-03-310001395064tak:DerivativeAssetsMember2021-03-310001395064tak:DerivativeLiabilitiesMember2021-03-310001395064tak:ShareBasedPaymentArrangementOptionMember2020-04-012021-03-310001395064tak:ShareBasedPaymentArrangementOptionMembertak:ShareBasedPaymentArrangementNonemployeeMember2020-04-012021-03-310001395064tak:ShareBasedPaymentArrangementEmployeeMembertak:ShareBasedPaymentArrangementOptionMember2020-04-012021-03-310001395064tak:ShareBasedPaymentArrangementEmployeeMembertak:ShareBasedPaymentArrangementOptionMember2018-04-012019-03-310001395064tak:ShareBasedPaymentArrangementEmployeeMembertak:ShareBasedPaymentArrangementOptionMember2019-04-012020-03-31tak:plan0001395064tak:BoardIncentivePlanMembertak:ShareBasedPaymentArrangementTrancheOneMember2020-04-012021-03-310001395064tak:BoardIncentivePlanMembertak:SharebasedPaymentArrangementTrancheTwoMember2020-04-012021-03-310001395064tak:BoardIncentivePlanMember2020-04-012021-03-310001395064tak:EmployeeStockOwnershipPlanMember2020-04-012021-03-310001395064tak:LongTermIncentivePlanLTIPMember2020-04-012021-03-310001395064tak:BoardIncentivePlanAndEmployeeStockOwnershipPlanMember2018-04-012019-03-310001395064tak:BoardIncentivePlanAndEmployeeStockOwnershipPlanMember2019-04-012020-03-310001395064tak:BoardIncentivePlanAndEmployeeStockOwnershipPlanMember2020-04-012021-03-310001395064tak:BoardIncentivePlanMember2019-03-310001395064tak:BoardIncentivePlanMember2020-03-310001395064tak:BoardIncentivePlanMember2021-03-310001395064tak:EmployeeStockOwnershipPlanMember2019-03-310001395064tak:EmployeeStockOwnershipPlanMember2020-03-310001395064tak:EmployeeStockOwnershipPlanMember2021-03-310001395064tak:EquitySettledLongTermIncentivePlanMember2021-03-310001395064tak:ShireMembertak:AmericanDepositarySharesMember2019-01-082019-01-080001395064tak:BoardIncentivePlanMember2018-03-310001395064tak:EmployeeStockOwnershipPlanMember2018-03-310001395064tak:EquitySettledLongTermIncentivePlanMember2020-03-310001395064tak:BoardIncentivePlanMember2018-04-012019-03-310001395064tak:EmployeeStockOwnershipPlanMember2018-04-012019-03-310001395064tak:BoardIncentivePlanMember2019-04-012020-03-310001395064tak:EmployeeStockOwnershipPlanMember2019-04-012020-03-310001395064tak:EmployeeStockOwnershipPlanMember2020-04-012021-03-310001395064tak:EquitySettledLongTermIncentivePlanMember2020-04-012021-03-310001395064tak:BoardIncentivePlanAndEmployeeStockOwnershipPlanMember2021-03-310001395064tak:BoardIncentivePlanAndEmployeeStockOwnershipPlanMember2019-03-310001395064tak:BoardIncentivePlanAndEmployeeStockOwnershipPlanMember2020-03-310001395064tak:PhantomStockAppreciationRightsAndRestrictedStockUnitsMember2019-04-012020-03-310001395064tak:PhantomStockAppreciationRightsAndRestrictedStockUnitsMember2020-04-012021-03-310001395064tak:PhantomStockAppreciationRightsAndRestrictedStockUnitsMember2018-04-012019-03-310001395064tak:PhantomStockAppreciationRightsAndRestrictedStockUnitsMember2020-03-310001395064tak:PhantomStockAppreciationRightsAndRestrictedStockUnitsMember2021-03-310001395064tak:PhantomStockAppreciationRightsMember2020-04-012021-03-310001395064tak:PhantomStockAppreciationRightsMember2018-03-310001395064tak:PhantomStockAppreciationRightsMember2019-03-310001395064tak:PhantomStockAppreciationRightsMember2020-03-310001395064tak:PhantomStockAppreciationRightsMember2018-04-012019-03-310001395064tak:PhantomStockAppreciationRightsMember2019-04-012020-03-310001395064tak:PhantomStockAppreciationRightsMember2021-03-310001395064tak:RestrictedStockUnitsMember2020-04-012021-03-310001395064tak:RestrictedStockUnitsMember2018-03-310001395064tak:RestrictedStockUnitsMember2019-03-310001395064tak:RestrictedStockUnitsMember2020-03-310001395064tak:RestrictedStockUnitsMember2018-04-012019-03-310001395064tak:RestrictedStockUnitsMember2019-04-012020-03-310001395064tak:RestrictedStockUnitsMember2020-04-012021-03-310001395064tak:RestrictedStockUnitsMember2021-03-310001395064tak:LiabilitySettledLongTermIncentivePlanMember2020-04-012021-03-310001395064tak:LiabilitySettledLongTermIncentivePlanMember2020-03-310001395064tak:LiabilitySettledLongTermIncentivePlanMember2020-04-012021-03-310001395064tak:LiabilitySettledLongTermIncentivePlanMember2021-03-310001395064tak:BoardIncentivePlanMembertak:ShareBasedPaymentArrangementTrancheOneMember2018-04-012019-03-310001395064tak:BoardIncentivePlanMembertak:ShareBasedPaymentArrangementTrancheOneMember2019-04-012020-03-310001395064tak:EmployeeStockOwnershipPlanMembertak:SharebasedPaymentArrangementTrancheTwoMember2018-04-012019-03-310001395064tak:EmployeeStockOwnershipPlanMembertak:SharebasedPaymentArrangementTrancheTwoMember2019-04-012020-03-310001395064tak:EmployeeStockOwnershipPlanMembertak:SharebasedPaymentArrangementTrancheTwoMember2020-04-012021-03-31tak:entity0001395064tak:TakedaAustriaGmbHMember2020-04-012021-03-310001395064tak:BaxterAGMember2020-04-012021-03-310001395064tak:BaxaltaInnovationsGmbHMember2020-04-012021-03-310001395064tak:TakedaDistribuidoraLtda.Member2020-04-012021-03-310001395064tak:TakedaCanadaIncMember2020-04-012021-03-310001395064tak:TakedaChinaHoldingsCo.Ltd.Member2020-04-012021-03-310001395064tak:TakedaPharmaceuticalChinaCompanyLimitedMember2020-04-012021-03-310001395064tak:TakedaChinaInternationalTradingMember2020-04-012021-03-310001395064tak:TakedaPharmaASMember2020-04-012021-03-310001395064tak:TakedaFranceS.A.S.Member2020-04-012021-03-310001395064tak:TakedaGmbHMember2020-04-012021-03-310001395064tak:TakedaIrelandLimitedMember2020-04-012021-03-310001395064tak:ShirePharmaceuticalsInternationalUnlimitedCompanyMember2020-04-012021-03-310001395064tak:ShirePharmaceuticalsIrelandLimitedMember2020-04-012021-03-310001395064tak:ShireAcquisitionsInvestmentsIrelandDesignatedActivityCompanyMember2020-04-012021-03-310001395064tak:ShireIrelandFinanceTradingLimitedMember2020-04-012021-03-310001395064tak:TakedaItaliaS.p.A.Member2020-04-012021-03-310001395064tak:NihonPharmaceuticalCo.Ltd.Member2020-04-012021-03-310001395064tak:TakedaPharmaceuticalsKoreaCo.Ltd.Member2020-04-012021-03-310001395064tak:TakedaASMember2020-04-012021-03-310001395064tak:TakedaPharmaceuticalsLimitedLiabilityCompanyMember2020-04-012021-03-310001395064tak:TakedaDevelopmentCenterAsiaPte.Ltd.Member2020-04-012021-03-310001395064tak:TakedaFarmaceuticaEspanaSAMember2020-04-012021-03-310001395064tak:TakedaPharmaceuticalsInternationalAGMember2020-04-012021-03-310001395064tak:BaxaltaGmbHMember2020-04-012021-03-310001395064tak:BaxaltaManufacturingS.r.l.Member2020-04-012021-03-310001395064tak:TakedaUKLimitedMember2020-04-012021-03-310001395064tak:TakedaDevelopmentCentreEuropeLtd.Member2020-04-012021-03-310001395064tak:ShirePharmaceuticalsLimitedMember2020-04-012021-03-310001395064tak:TakedaPharmaceuticalsU.S.A.Inc.Member2020-04-012021-03-310001395064tak:MillenniumPharmaceuticalsInc.Member2020-04-012021-03-310001395064tak:ARIADPharmaceuticalsInc.Member2020-04-012021-03-310001395064tak:TakedaCaliforniaInc.Member2020-04-012021-03-310001395064tak:TakedaVaccinesInc.Member2020-04-012021-03-310001395064tak:TakedaDevelopmentCenterAmericasInc.Member2020-04-012021-03-310001395064tak:BaxaltaIncorporatedMember2020-04-012021-03-310001395064tak:DyaxCorp.Member2020-04-012021-03-310001395064tak:ShireHumanGeneticTherapiesIncMember2020-04-012021-03-310001395064tak:BioLifePlasmaServicesLPMember2020-04-012021-03-31tak:subsidiary0001395064tak:AmatoPharmaceuticalProductsLtd.Member2020-04-012021-03-310001395064ifrs-full:AssociatesMember2019-04-012020-03-310001395064ifrs-full:AssociatesMember2020-04-012021-03-310001395064tak:ShireMember2019-01-08iso4217:USDxbrli:shares0001395064tak:ShireMembertak:NewTakedaSharesMember2019-01-082019-01-080001395064tak:ShireMember2019-01-082019-01-080001395064ifrs-full:GoodwillMembertak:ShireMember2019-01-080001395064tak:ShireMember2018-04-012019-03-310001395064tak:TiGenixMember2018-06-080001395064tak:TiGenixMember2018-04-300001395064tak:TiGenixMember2018-04-302018-06-080001395064tak:TiGenixMember2018-04-302018-04-3000013950642018-11-282018-11-2800013950642015-04-302015-04-30tak:lawsuit0001395064tak:OutsideOfTheUnitedStatesMember2021-03-31tak:notice00013950642019-01-282019-01-280001395064country:US2013-12-310001395064tak:USDJapanBankForInternationalCooperation2019Membertak:RepaymentOfBorrowingsMember2021-04-012021-04-010001395064tak:RepaymentOfBorrowingsMembertak:USDUnsecuredSeniorNotesMember2021-04-162021-04-16

tak-20210331_g1.jpg
1


As filed with the Securities and Exchange Commission on June 29, 2021
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________________________
FORM 20-F
___________________________________________________________
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended March 31, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from      to     
OR
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report
Commission file number: 001-38757
___________________________________________________________
Takeda Yakuhin Kogyo Kabushiki Kaisha
(Exact name of registrant as specified in its charter)
___________________________________________________________
Takeda Pharmaceutical Company Limited
(Translation of registrant’s name into English)
___________________________________________________________
Japan
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668, Japan
(Jurisdiction of incorporation or organization)(Address of principal executive offices)
Costa Saroukos
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668, Japan
Tel: +81 3 3278-2306
Fax: +81 3 3278-2268
Email: Global.External.Reporting@takeda.com
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
___________________________________________________________
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbols
Name of Each Exchange On Which Registered 
American Depositary Shares Representing Common Stock
Common Stock, no par value
*
TAKNew York Stock Exchange
0.750% Senior Notes due 2027TAK27New York Stock Exchange
1.000% Senior Notes due 2029TAK29New York Stock Exchange
1.375% Senior Notes due 2032TAK32New York Stock Exchange
2.000% Senior Notes due 2040TAK40ANew York Stock Exchange
*Listed not for trading, but only in connection with the registration of the American Depositary Shares, pursuant to the requirements of the Securities and Exchange Commission.
Securities registered or to be registered pursuant to Section 12(g) of the Act:
None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:
None
___________________________________________________________
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.
157,132,028 ADSs outstanding as of March 31, 2021
1,563,358,159 shares of common stock as of March 31, 2021

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes ý      No ☐
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.      Yes ☐      No ý
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ý     No ☐
Indicate by check mark whether the registrant has submitted electronically every interactive data file required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ý    No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one): 
Large accelerated filerýAccelerated filer Non-accelerated filerEmerging growth company
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act.    ☐
† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. 
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
U.S. GAAP  ☐
International Financial Reporting Standards as issued
by the International Accounting Standards Board  
ý
Other  ☐
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.    ☐ Item 17    ☐ Item 18
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes ☐      No
(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.       Yes ☐      No ☐
1

TABLE OF CONTENTS
2


3

As used in this annual report, references to the “Company,” “Takeda,” “we,” “us” and “our” are to Takeda Pharmaceutical Company Limited and, except as the context otherwise requires, its consolidated subsidiaries.
In this annual report, we present our audited consolidated financial statements as of March 31, 2020 and 2021 and for the fiscal years ended March 31, 2019, 2020 and 2021. Our consolidated financial statements are prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). The term IFRS also includes International Accounting Standards (“IAS”) and the related interpretations of the committees (Standard Interpretations Committee (“SIC”) and International Financial Reporting Interpretations Committee (“IFRIC”)).
As used in this annual report, “yen,” “¥” or “JPY” means the lawful currency of Japan, “U.S. dollar,” “$” or “USD” means the lawful currency of the United States of America (“U.S.”) and “euro,” “€” or “EUR” means the lawful currency of the member states of the European Monetary Union.
As used in this annual report, “ADS” means an American Depositary Share, representing 0.5 shares of the Company’s common stock, and “ADR” means an American Depositary Receipt evidencing one or more ADSs. See “Item 12. Description of Securities Other Than Equity Securities—D. American Depositary Shares.” “Notes” refers to the series of notes issued by us and registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) listed on the cover page of this annual report. References to “our securities” refer to collectively to our ADSs, the shares of our common stock and the notes.
As used in this annual report, except as the context otherwise requires, the “Companies Act” means the Companies Act of Japan.
Amounts shown in this annual report have been rounded to the nearest indicated digit unless otherwise specified. In tables and graphs with rounded figures, sums may not add up due to rounding.
4

Special Note Regarding Forward-Looking Statements
This annual report contains forward-looking statements. These statements appear in a number of places in this annual report and include statements regarding the intent, belief, or current and future expectations of our management with respect to our business, financial condition and results of operations. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “intend,” “project,” “plan,” “aim,” “seek,” “target,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or the negative of these terms or other similar terminology. These statements are not guarantees of future performance and are subject to various risks and uncertainties. Actual results, performance or achievements, or those of our industry, may differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. In addition, these forward-looking statements are necessarily dependent upon assumptions, estimates and data that may be incorrect or imprecise and involve known and unknown risks and uncertainties. These forward-looking statements involve statements regarding:
our goals and strategies;
our ability to develop and bring to market new products;
expected changes in our revenue, costs, expenditures, operating income or other components of our results;
expected changes in the pharmaceutical industry or in government policies and regulations relating to it;
the ability to achieve the expected benefits of businesses we may acquire, including our acquisition of Shire plc (including, except as the context otherwise requires, its consolidated subsidiaries “Shire”);
developments regarding or the outcome of any litigation or other legal, administrative, regulatory or governmental proceedings;
information regarding competition within our industry;
the impact of the COVID-19 pandemic; or
the effect of economic, political, legislative or other developments on our business or results of operations.
Forward-looking statements regarding operating income and operating results are particularly subject to a variety of assumptions, some or all of which may not be realized. Accordingly, the forward-looking statements included in this annual report should not be interpreted as predictions or representations of future events or circumstances.
Potential risks and uncertainties include those identified and discussed in “Item 3. Key Information—D. Risk Factors,” “Item 5. Operating and Financial Review and Prospects,” “Item 4. Information on the Company” and elsewhere in this annual report. Given these risks and uncertainties, undue reliance should not be placed on any forward-looking statements, which speak only as of the date of this annual report. Except as required by law, we disclaim any obligation to update or review any forward-looking statements contained in this annual report, whether as a result of new information, future events or otherwise.

Item 1. Identity of Directors, Senior Management and Advisers
A. Directors and Senior Management
Not applicable.
B. Advisers
Not applicable.
C. Auditors
Not applicable.
Item 2. Offer Statistics and Expected Timetable
A. Offer Statistics
Not applicable.
B. Method and Expected Timetable
Not applicable.

5

Item 3. Key Information
A. Selected Financial Data
The following table presents selected financial information as of and for the fiscal years ended March 31, 2017, 2018, 2019, 2020, and 2021 derived from our consolidated financial statements. These financial statements are prepared in accordance with IFRS.
The selected consolidated financial information set forth below should be read in conjunction with Item 5. “Operating and Financial Review and Prospects” and our consolidated financial statements and notes thereto included in this annual report.
For the fiscal year ended March 31,
20172018201920202021
(billions of yen, except share and per share data and where designated as U.S. dollar)
Selected Statements of Operations Data:
Revenue¥1,732.1 ¥1,770.5 ¥2,097.2 ¥3,291.2 ¥3,197.8 
Operating profit155.9 241.8 237.7 100.4 509.3 
Share of profit (loss) of investments accounted for using the equity method(1.5)(32.2)(43.6)(24.0)0.1 
Profit (loss) before tax143.3 217.2 127.6 (60.8)366.2 
Net profit for the year115.5 186.7 135.1 44.3 376.2 
Net profit attributable to owners of the Company
114.9 186.9 135.2 44.2 376.0 
Per share amounts
Basic earnings¥147.15 ¥239.35 ¥140.61 ¥28.41 ¥240.72 
Diluted earnings146.26 237.56 139.82 28.25 238.96 
Annual cash dividends180.00 180.00 180.00 180.00 180.00 
Cash dividends in U.S. dollars(1)
$1.62 $1.69 $1.63 $1.67 $1.63 
Selected Statements of Financial Position Data:
Cash and cash equivalents¥319.5 ¥294.5 ¥702.1 ¥637.6 ¥966.2 
Total assets4,346.8 4,106.5 13,792.8 12,821.1 12,912.3 
Total bonds and loans1,144.9 985.7 5,751.0 5,093.3 4,635.4 
Total liabilities2,397.8 2,089.1 8,606.8 8,093.6 7,735.1 
Total equity1,949.0 2,017.4 5,186.0 4,727.5 5,177.2 
Share capital65.2 77.9 1,643.6 1,668.1 1,668.1 
Other Data:
Number of shares issued at end of period (in thousands)
790,521 794,688 1,565,006 1,576,374 1,576,388 
____________
Note:
(1)Calculated using the Japanese yen—U.S. dollar exchange rate as of March 31 of each respective year, based on the noon buying rate in New York City for cable transfers in foreign currencies as certified for customs purposes by the Federal Reserve Bank of New York.
B. Capitalization and Indebtedness
Not applicable.
C. Reasons for the Offer and Use of Proceeds
Not applicable.
6

D. Risk Factors
Any investment in our securities involves risk. Investors should carefully consider, in light of their own financial circumstances and investment objectives, the following risks before making an investment decision with respect to our securities. If any of the following risks actually occur, it could have a material adverse effect on our business, financial condition, results of operations, future prospects, and the market value of our securities.
The risks discussed below are those that we believe are material, but these risks and uncertainties may not be the only risks that we face. Additional risks that are not known to us at this time, or that are currently believed to be not material, could also have a material adverse effect on our business, financial condition, results of operations, future prospects and the market value of our securities.  
 Risks Relating to Development, Production and Marketing of Pharmaceutical Products
Research and development of pharmaceutical products are expensive and subject to significant uncertainties, and we may be unsuccessful in bringing commercially successful products to market or recouping development costs.
Our ability to offset the effects of losses of exclusivity in our existing products and to continue to grow our business depends significantly on the success of our research and development activities in identifying, developing and successfully commercializing new products in a timely and cost-effective manner. To accomplish this, we commit substantial efforts, funds and other resources to research and development, both in-house and through collaborations with third parties. However, these research and development programs are expensive and involve intensive preclinical evaluation and clinical trials in connection with a highly complex and lengthy regulatory approval process. We discuss regulatory considerations below under “—If we fail to comply with government regulations over product development, regulatory approvals and reimbursement requirements, our business could be adversely affected.” The research and development process for a new biopharmaceutical product also requires us to attract and retain sufficient numbers of highly-skilled employees and can often take more than ten years from discovery to commercial launch. Even if we successfully develop and bring to market new products, there is only a limited available patent life in which to recoup these development costs.
During each stage of the approval process and post-approval life cycle of our products, there is a substantial risk that we will encounter serious obstacles, including unfavorable results or indications of safety concerns regarding a new compound; difficulty or delays in enrolling patients or administering in clinical trials; delays in completing formulation and other testing and work necessary to support an application for regulatory approval; insufficient clinical trial data to support the safety or efficacy of the product candidate; failure to bring a product to market prior to a competitor, or to develop a product sufficiently differentiated from a competing product to achieve significant market share; difficulty in obtaining reimbursement at satisfactory rates for our approved products from governments and insurers; difficulty in obtaining regulatory approval for additional indications; failure to enter into or implement successful alliances for the development and/or commercialization of products or the inability to manufacture sufficient quantities of a product candidate for development or commercialization activities in a timely or cost-efficient manner. Moreover, the degree of market acceptance of any approved product candidate by the medical community, including physicians, healthcare professionals and patients, will depend on a number of factors, including relative convenience and ease of administration, the prevalence and severity of any adverse reactions, availability of alternative treatments, pricing and our sales and marketing strategy. Activities described above become more difficult during pandemics, such as the COVID-19 pandemic, which may result in more serious obstacles to advance research and development efforts.
In addition, to the extent that new regulations raise the costs of obtaining and maintaining product authorizations or limit the economic value of a new product to its originator, our profitability and growth prospects could be diminished. Development of new and innovative products can also require the use of emerging platforms and technologies for which regulations either do not yet exist or are under development or modification. This may lead to greater uncertainty and risk in establishing the necessary data for approvals to conduct clinical trials and/or receiving marketing approvals.
As a result of the foregoing or other factors, we may decide to abandon the development of potential pipeline products in which we have invested significant resources, even where the product is in the late stages of development. Moreover, there can also be no assurance that we will be successful in bringing new products to market, marketing them, achieving sufficient acceptance thereof and recouping our investments in their development. For example, our pipeline compounds may not receive regulatory approval, become commercially successful or achieve satisfactory rates of reimbursement. Additionally, products approved for use and successfully marketed in one market may be unable to obtain regulatory approval, become commercially successful or achieve satisfactory rates of reimbursement in other markets. As a result, we may be unable to earn returns on investments that we originally anticipated or at all, or may be forced to revise our research and development strategy, and our business, financial condition and results of operations could be materially and adversely affected.
If we fail to comply with government regulations over product development, regulatory approvals and reimbursement requirements, our business could be adversely affected.
Obtaining marketing approval for pharmaceutical products is a lengthy, complex and highly regulated process that requires intensive preclinical and clinical data, and the approval process can vary significantly depending on the regulatory authority. Relevant health authorities may, at the time of the filing of the application for a marketing authorization, or later during their review, impose requirements that can evolve over time, including requiring additional clinical trials, and such authorities may delay or refuse to grant approval. Even where we have obtained marketing approval for a product in one or more major markets, we may need to invest significant time and resources in applying for approval in other markets, and there is no assurance that we will be able to obtain such approval. In recent years, health authorities have become increasingly focused on product safety and on the risk/benefit profile of pharmaceutical products, which could lead to more burdensome and costly approval processes and
7

negatively affect our ability to obtain regulatory approval for products under development. For example, the U.S. Food and Drug Administration (the “FDA”), the European Medicines Agency (the “EMA”), the Pharmaceuticals and Medical Devices Agency (the “PMDA”) in Japan and National Medical Products Administration (the “NMPA”) for China have been implementing strict requirements for approval, particularly in terms of the volume of data needed to demonstrate a product’s efficacy and safety.
Even after regulatory approval is obtained, marketed products are subject to various post-marketing commitments, including continual review, risk evaluations, comparative effectiveness studies and, in some cases, requirements to conduct post-marketing clinical trials to gather additional safety and other data. Regulatory authorities in many countries have worked to enhance post-approval monitoring in recent years, which has increased post-approval regulatory burdens. Post-regulatory approval reviews and data analyses can lead to the issuance of recommendations by government agencies, specialized organizations, health professionals or patients regarding the use of products. For example, such recommendations could include a request to limit the patient population of a drug’s indication, the imposition of marketing restrictions, including changes in package insert or labeling, or the suspension or withdrawal of the product. Any such recommendation, whether implemented or not, could result in reductions in sales volume and/or new or increased concerns about the adverse reactions or efficacy of a product. These substantial regulatory requirements have, over time, increased the costs associated with maintaining regulatory approvals and achieving reimbursement for our products.
If the regulatory approval process or post-approval, reimbursement, monitoring or other requirements become significantly more burdensome in any of our major markets, we could become subject to increased costs and may be unable to obtain or maintain approval to market our products. Any such adverse changes could materially and adversely affect our business, results of operations or financial condition.
If we fail to comply with laws and regulations governing the sales and marketing of our products, our business could be adversely affected.
We engage in various marketing, promotional and educational activities pertaining to, as well as the sale of, pharmaceutical products in a number of jurisdictions around the world. The promotion, marketing and sale of pharmaceutical products and medical devices is highly regulated and the sales and marketing practices of market participants have been subject to increasing supervision by governmental authorities, and we believe that this trend will continue.
In the U.S., our sales and marketing activities are monitored by a number of regulatory authorities and law enforcement agencies, including the U.S. Department of Health and Human Services (the “HHS”), the FDA, the U.S. Department of Justice, the U.S. Securities and Exchange Commission (the “SEC”) and the Drug Enforcement Administration (the “DEA”). These authorities and agencies and their equivalents in other countries have broad authority to investigate market participants for potential violations of laws relating to the sale, marketing and promotion of pharmaceutical products and medical devices, including the False Claims Act, the Anti-Kickback Statute, the United Kingdom Bribery Act of 2010 and the Foreign Corrupt Practices Act, among others, for alleged improper conduct, including corrupt payments to government officials, improper payments to medical professionals, off-label marketing of pharmaceutical products and medical devices, and the submission of false claims for reimbursement by the federal government. Healthcare companies may also be subject to enforcement actions or prosecution for such improper conduct. Any inquiries or investigations into our operations, or enforcement or other regulatory action against us, by such authorities could result in significant defense costs, fines, penalties and injunctive or administrative remedies, distract management to the detriment of the business, result in the exclusion of certain products, or us as a whole, from government reimbursement programs or subject us to regulatory controls or government monitoring of its activities in the future. We are also subject to certain ongoing investigations by governmental agencies.
Government policies and other pressures to reduce medical costs could have an adverse effect on sales of our pharmaceutical products.
We are subject to governmental regulations mandating price controls in various countries in which we operate. The growth of overall healthcare costs as a percentage of gross domestic product in many countries means that governments and consumers are under intense pressure to control spending even more tightly. See Item 4. Information on the Company—B. Business Overview-Third Party Reimbursement and Pricing.
In the U.S., there has been increasing pricing pressure from managed care groups and institutional and governmental purchasers. As managed care groups have grown in size due to market consolidation, pharmaceutical companies have faced increased pressure in pricing and usage negotiations, and there is fierce competition among pharmaceutical companies to have their products included in the care providers’ formularies. Moreover, as a result of the legislative and regulatory environment, in the U.S. we continue to experience heightened pricing pressure on, and limitations on access to, our branded pharmaceutical products sold in the U.S. There has been increasing attention paid to the level of pricing of pharmaceutical products by policymakers and stakeholders, which could lead to political pressure or legislative, regulatory or other efforts to introduce lower prices, and change how the pharmaceutical supply chain could operate. In addition, there are efforts by the federal government to reduce spending on the Medicare and Medicaid programs, expand the Affordable Care Act, and lower the overall spending by the government on prescription medicines. The future of U.S. healthcare legislation, as well as the potential impact of any new legislation, is uncertain, but we expect the health care industry in the U.S. will continue to be subject to increased pricing and spending pressure, including from regulation and political and legal action.
In Japan, manufacturers of pharmaceutical products must have new products listed on the National Health Insurance (the “NHI”), a price list published by the Ministry of Health, Labour and Welfare of Japan (the “MHLW”). The NHI price list provides rates for calculating the price of pharmaceutical products used in medical services provided under various public medical care insurance systems. Prices on the NHI price list have been previously subject to revisions based on the actual prices at which the pharmaceutical products are purchased by medical institutions in Japan after discounts and rebates from the listed price, and the average price of previously listed products generally decreases as a result of these price revisions. The Japanese government is currently undertaking healthcare reform initiatives with the goal of sustaining the universal coverage of the NHI program. As part of these initiatives, the annual NHI price list revision was introduced in April 2021, which could lead to more frequent
8

downward price revisions. The government is also addressing the efficient use of drugs, including the further promotion of generic use that slightly falls short of a target of 80% penetration by volume by September 2020 with respect to products for which market exclusivity has expired. In addition, a cost-effectiveness evaluation has been officially introduced by the MHLW since April 2019. Products on the NHI price list nominated based on pre-defined criteria, such as the innovativeness and the financial impact, will be subject to review, and subject to price adjustments depending on the outcome of this review.
In Europe, as in the U.S., drug prices have been subject to downward pressure due to measures implemented in each country to control drug costs, and prices continue to come under pressure due to parallel imports, generic competition, increasing use of health technology assessment based upon cost-effectiveness and other factors. European pricing and reimbursement authorities have also intensified efforts to increase transparency of prices as well as exchange of information among the various European pricing authorities in order to raise pressure towards the industry. This pricing debate has impacted the overall political climate in Europe and has triggered a European policy initiative to review the pharmaceutical industry’s intellectual property incentives with a particular emphasis on orphan drugs. Any new legislation in this area would take at least two to three years to be adopted but could have significant impact on our business model.
We are also facing similar pricing pressures in other regions, such as various emerging countries including China. We expect such pricing pressures to continue as we expand our business in those regions and countries.
We expect these efforts to control costs to continue as healthcare payers around the globe, in particular government-controlled health authorities, publicly funded or subsidized health programs, insurance companies and managed care organizations (the “MCOs”), increasingly pursue initiatives to reduce the overall cost of healthcare, restrict access to higher-priced new medicines, increase the use of generics and impose overall price revisions. Such further implementation of these policies could have a material adverse effect on our business, financial condition and results of operations.
The expiration or loss of patent or regulatory data protection over our products or patent infringement by generic manufacturers could lead to significant competition from generic versions of the relevant product and lead to declines in market share and price levels of our products.
Our pharmaceutical products are generally protected for a defined period by various patents (including those covering drug substance, drug product, approved indications, methods of administration, methods of manufacturing, formulations and dosages) and/or regulatory exclusivity, which are intended to provide us with exclusive rights to market the products for the life of the patent or duration of the regulatory data protection period. The loss of market exclusivity for pharmaceutical products opens such products to competition from generic substitutes that are typically priced significantly lower than the original products, which typically adversely affects the market share and prices of the original products.
Generic substitutes have high market shares in a number of key markets, including the U.S., Europe and many emerging countries, and the adverse effects of the launch of generic products are particularly significant in such markets. The introduction of generic versions of a pharmaceutical product typically leads to a swift and substantial decline in the sales of the original product. Our active life cycle management efforts cannot fully mitigate the impact of competition from generics. In the U.S. and the European Union (“EU”), for example, political pressure to reduce spending on prescription drugs has led to legislation and other measures that encourage the use of generic products. In Japan, the government is implementing various measures to control drug costs, including by encouraging medical practitioners to use and prescribe generic drugs, and in April 2021 announced its intention to raise generic drug penetration with respect to products for which market exclusivity has expired, to 80% by volume in all prefectures (regions) by the end of the fiscal year-ending 2023. Legislation has also been passed in the U.S. and Europe encouraging the use of biosimilar products. Similar to generics, biosimilars aim to provide less expensive versions of innovative biologic products. New legislation has provided abbreviated pathways for the approval and marketing of biosimilar products, which may affect the profitability and commercial viability of our biologic products.
Certain products of ours have begun to, or are expected over the next several years to, face declining sales due to the loss of market exclusivity. For example, following the expiration of patent protection covering bortezomib, the active ingredient in VELCADE, one of our largest selling products in the U.S., a competing bortezomib-containing product has been introduced. Although the market share impact to date has not been large due to the limitations of the competing product’s formulation, further entry of competing products, particularly with a subcutaneous administration route, could result in an acceleration of revenue declines. Such decreases may accelerate further following the scheduled expiration of patent protection covering the formulation of VELCADE in 2022. Patent protections covering VYVANSE, are scheduled to expire in the U.S. in 2023, which we anticipate will lead to declines in sales. Based on current data and marketing exclusivities, the period of regulatory exclusivity for ENTYVIO, which is currently our top selling product, may continue until, at the earliest, 2024 in the EU and 2026 in the U.S. and Japan, and we expect to see decreased sales of ENTYVIO in the long term as a result. There are also patents for ENTYVIO that expire in 2032, and therefore the exact timing of biosimilar entry is uncertain at this time.
We may also be subject to competition from generic drug manufacturers prior to the expiration of patents if a manufacturer successfully challenges the validity of our patents, if the generic manufacturer is able to design around our patents, or if the manufacturer obtains approval of their product and launches it at risk (i.e. prior to a judicial determination). If such a launch occurred prior to completion of court proceedings, a court may decline to grant a preliminary injunction. While we may be entitled to obtain damages subsequently, the amount we may ultimately be awarded and able to collect may be insufficient to compensate for the loss of sales and other harm caused to us. Furthermore, if we lose patent protection as a result of an adverse court decision or a settlement, in certain jurisdictions, we may face the risk that government and private third-party payers and purchasers of pharmaceutical products may claim damages alleging they have over-reimbursed or overpaid for a drug.
If our patent and other intellectual property rights are infringed by generic drug manufacturers or other third parties, we may not be able to take full advantage of the potential or existing demand for our products. The protection that we are able to obtain for our prescription drugs varies from product to product and country to country and may not always be sufficient because of local variations in issued patents, or differences in national law or legal systems, including inconsistency in the enforcement or application of law and limitations on the availability of meaningful legal
9

remedies. In particular, patent protection in emerging markets is often less certain than in developed markets. Certain countries may also engage in compulsory licensing of pharmaceutical intellectual property to other manufacturers as a result of local political pressure. Furthermore, the attention of our management and other personnel could be diverted from their normal business activities if we decide to litigate against such infringement. The realization of any such risks could adversely and materially affect our business, financial condition and results of operations.
We may have difficulty maintaining the competitiveness of our products.
The pharmaceutical industry is highly competitive, and in order to maintain the competitiveness of our product portfolio, we are required to maintain ongoing, extensive research for technological innovations, including new compounds, to develop and commercialize existing pipeline products, to expand our product portfolio through acquisitions, partnerships and in-licensing, and to market our products effectively, including by communicating the efficacy, safety and value of our products to healthcare professionals. However, healthcare professionals and consumers may choose competitors’ products over ours, if they perceive these products to be safer, more reliable, more effective, easier to administer or less expensive. The success of any product depends on our ability to effectively communicate with and educate healthcare professionals and patients and convince them of the advantage of our products over those of our competitors. We often carry out costly clinical trials even after our products have been launched to produce data to be utilized for these purposes, but such trials do not always produce the desired outcomes. Certain competitors have greater financial and other resources to conduct such trials in more detail and with larger patient populations, which may ultimately enable them to promote their products more effectively than we do. Furthermore, if relevant regulators increase their approvals of new therapies developed by competitors for the conditions treated by our products, such as in order to increase the number of treatment options available for rare or orphan diseases, our business and results of operations could be materially and adversely affected.
In recent years, competitors have introduced novel hemophilia products, or such products have been approved for additional uses, which may affect (and in certain cases has affected) sales of our recombinant and plasma-based hemophilia products, such as our factor FVIII products and FEIBA. Certain competitors are developing other hemophilia therapies, including gene-based therapies, which, if successfully introduced, could also affect sales of our recombinant and plasma-based therapies. Increased competition from new products or therapies could similarly affect our other products.
In Japan, the steady introduction of drugs already marketed outside Japan by overseas competitors has led to increased competition. In addition, new competing products or the development of superior medical technologies and other treatment options could make our products or technologies lose their competitiveness or become obsolete. As discussed above, our products are also subject to competition from inexpensive generic versions or biosimilars of our products, as well as those of our competitors’ products, upon the expiration or loss of related patent protection and regulatory data protection, which may result in loss of market share. If we are unable to maintain the competitiveness of our products, our business, financial position and results of operations could be materially and adversely affected.
Furthermore, sales of the rare disease portfolio are particularly concentrated among small groups of customers, and we may be disproportionately affected by changes in their purchasing patterns, including if we are unable to maintain the competitiveness of our products.
We may not be able to adequately expand our product portfolio through third-party alliance arrangements.
We expect that we will continue to collaborate with third parties for key aspects of our business, including the discovery and development of new products, in-licensing products, and the marketing and distribution of approved products. A major part of our research and development strategy is to initiate alliances with third parties in the biotechnology industry, academia and the public sector, and we believe that the overall strength of our research and development program and product pipeline depends on our ability to identify and initiate partnerships, in-licensing arrangements and other collaborations with third parties. However, there can be no assurance that any of our third-party alliances will lead to the successful development and marketing of new products. Moreover, reliance on third-party alliances subjects us to a number of risks, including:
We may be unable to identify suitable opportunities at a reasonable cost and on terms that are acceptable to us due to active and intense competition among pharmaceutical groups for alliance opportunities or other factors;
Entering into in-licensing or partnership agreements may require the payment of significant milestones well before the relevant products are placed in the market, without any assurance that such investments will ultimately become profitable in the long term. To the extent such milestone payments are recorded as assets on our consolidated statement of financial position, any termination of the relevant partnership could require us to recognize an impairment loss up to the full value of such assets;
When we research and market our products through collaboration arrangements, the performance of certain key tasks or functions are the responsibility of our collaboration partners, who may not perform effectively or otherwise meet our expectations; and
Decisions may be under the control of or subject to the approval of our collaboration partners, and we may have differing views or be unable to agree upon an appropriate course of action. Any conflicts or difficulties that we may have with our partners during the course of these agreements or at the time of their renewal or renegotiation or any disruption in the relationships with our partners may affect the development, launch and/or marketing of certain of our products or product candidates.
In addition, a licensor or partner may attempt to terminate its license or partnership agreement with us or elect not to renew it to pursue other marketing opportunities. Our licensors or partners also could merge with or be acquired by another company or experience financial or other setbacks unrelated to our alliance arrangements. Any of these events may force us to abandon a development project and adversely affect our ability to adequately expand or maintain our product portfolio.

10

Our use of third parties for the performance of certain key business functions, particularly product manufacture and commercialization, heightens the risks faced by our business.
We commonly use suppliers, vendors and partners, including alliances with other pharmaceutical companies, for certain key aspects of our business, including manufacturing and commercialization of products, support for information technology systems and certain human resource functions. We do not control these partners, but we depend on them in ways that may be significant to us. If these parties fail to meet our expectations or fulfill their obligations to us, we may fail to receive the expected benefits. In addition, if any of these third parties fails to comply with applicable laws and regulations in the course of its performance of services for us, there is a risk that we may be held responsible for such violations as well. This risk is particularly serious in emerging markets, where corruption is often prevalent and where many of the third parties on which we rely do not have internal compliance resources comparable to our own. Any such failures by third parties, in emerging markets or elsewhere, could adversely affect our business, reputation, financial condition or results of operations.
Our dependence on third parties for the inputs for our products subjects us to various risks, and changes in the costs of materials may adversely affect our profitability.
Although we develop and manufacture the active ingredients used in some of our products at our own facilities, we are dependent on third-party suppliers for a substantial portion of the raw materials and compounds used in the products we produce. The price and availability of the raw materials for our products, including chemical compounds and biologics, are subject to the effects of weather, natural disasters, market forces, the economic environment, fuel costs and foreign exchange rates. If our cost for such materials increases, we may not be able to make corresponding increases in the prices of our products due to regulations, market conditions or our relationships with our customers, and as a result, our profitability could be materially and adversely affected.
In particular, we rely on third-party suppliers of key manufacturing inputs of certain drug products. Furthermore, certain active ingredients for these products are sourced from a single supplier. We also rely in part on third-party sources to provide the donated plasma necessary for our plasma-derived therapies. In addition, although we dual-source certain key products and/or active ingredients, we currently rely on a single source for production of certain final drug products. Sources of some materials may be limited to a single supplier, and if such a supplier faces any difficulty in supplying the materials, we may not be able to find an alternative supplier in a timely manner or at all. If materials become unavailable or if quality problems related to the materials arise, we may be forced to halt production and sales of products that use them. In the event that any of our third-party suppliers is delayed in its delivery of such raw materials or compounds, is unable to deliver the full quantity ordered by us at the appropriate level of quality, or is unable to deliver any raw materials or compounds at all, our ability to sell our products in the quantities demanded by the market may be impaired, which could damage our reputation and relationships with customers and patients. In such a case, our business and results of operations could be adversely affected.
The manufacture of our products is technically complex and highly regulated, and supply interruptions, product recalls or other production problems caused by unforeseen events may reduce sales, adversely affect our operating results and financial condition and delay the launch of new products.
The manufacture of our products is technically complex and highly regulated, and as a result we may experience difficulties or delays including but not limited to seizure or recalls of products or shut-downs of manufacturing plants; problems with business continuity, including as a result of a natural or man-made disaster, at one of our facilities or at a critical supplier or vendor; failure by us or by any of our vendors or suppliers to comply with the Good Manufacturing Practice (the “GMP”) and other applicable regulations and quality assurance guidelines, which could lead to manufacturing shutdowns, product shortages, delays in product manufacturing and /or administrative, enforcement or other actions by regulatory authorities if regulatory authorities deem our products to be adulterated or otherwise in violation of applicable laws; problems with manufacturing, quality assurance/quality control or supply, or governmental approval delays, due to our consolidation and rationalization of manufacturing facilities and the sale or closure of certain sites; failure of a sole source or single source supplier to provide us with necessary raw materials, supplies or finished goods for an extended period of time, which could impact continuous supply; failure of a third-party manufacturer to supply us with semi-finished or finished products on time; construction or regulatory approval delays related to new facilities or the expansion of existing facilities; the inability to obtain sufficient components or raw materials on a timely basis or at a cost-effective price due to public health crises, medical epidemics or pandemics such as the COVID-19 pandemic; additional costs related to deficiencies identified by regulatory agencies in connection with inspections of our facilities, and enforcement, remedial or punitive actions by regulatory authorities if we fail to remedy any deficiencies; and other manufacturing or distribution problems including limits to manufacturing capacity due to regulatory requirements (e.g. Registration, Evaluation, Authorisation and Restriction of Chemicals (“REACH”) regulation in the EU), changes in the types of products produced, physical limitations or other business interruptions that could impact continuous supply.
In addition, despite efforts at compliance, from time to time we or our partners may receive notices of manufacturing, quality-related, or other observations following inspections by regulatory authorities around the world, as well as official agency correspondence regarding compliance. For example, on June 9, 2020 the FDA issued a warning letter related to our manufacturing plant in Hikari, Yamaguchi, Japan which included several technical observations, including observations about procedures, personnel, records, investigations, training, equipment, and oversight. We responded to the warning letter within the required timeframe and the Hikari plant is currently working under the comprehensive corrective action/preventative action plan. The issues raised as part of the inspection are being addressed within the context of those activities. The corrective actions resulted in a temporary supply shortage of Leuprorelin, a product which we supply to AbbVie, Inc. (“AbbVie”) pursuant to a supply agreement. AbbVie has since filed a lawsuit against us on November 6, 2020 specifying an alleged breach of contract. We or our partners may receive additional or similar observations, correspondence and claims in the future, whether regarding the Hikari plant or otherwise. If we are unable to resolve these observations and address regulator concerns and claims from partners in a timely fashion, our business, financial condition and results of operations could be
11

materially affected. See “—We are involved in litigation relating to our operations on an ongoing basis, and such litigation could result in financial losses or harm our business” for further discussion on risks associated with litigation and lawsuits relating to our operations.
The development and manufacture of biologics and stem cell therapies present heightened or additional risks. The manufacture of biologics, including stem cell products, is highly complex and is characterized by inherent risks and challenges, such as raw material inconsistencies, logistical and sourcing challenges, significant quality control and assurance requirements, manufacturing complexity (including heightened regulatory requirements) and significant manual processing. Unlike products that rely on chemicals for efficacy, such as most pharmaceuticals, biologics are difficult to characterize due to the inherent variability of biological input materials. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in, among other things, lot failures, product recalls, product liability claims or insufficient inventory, which could be costly to us or result in reputational damage.
Furthermore, sourcing and transportation of plasma and production and distribution of plasma-derived products is complex, capital intensive and subject to extensive regulation. Efforts to increase the collection of plasma may require strengthening acquisition and third-party contracting capacities and successful regulatory approval of additional plasma collection facilities and plasma fractionation facilitates. Further development of such capacities and facilities involve a lengthy regulatory process and is highly capital intensive. In addition, access to and transport and use of plasma may be subject to restrictions by governmental agencies. If we are unable to manage these inherent risks and challenges, we may lose market share or customer confidence, be required to record charges related to idle capacity or impairment on facilities or take other actions which could materially and adversely affect the Plasma-Derived Therapies business.
Any of the above may reduce sales, delay the launch of new products, and adversely affect our business, financial condition and results of operations.
The illegal distribution and sale by third parties of counterfeit versions of our products or products stolen from us could have an adverse effect on our reputation and business.
Third parties may illegally distribute and sell counterfeit versions of our products, which do not meet the rigorous manufacturing and testing standards to which our products are subject. A patient who receives a counterfeit drug may be at risk for a number of dangerous health consequences. Reports of adverse reactions to counterfeit drugs or increased levels of counterfeiting could materially affect patient confidence in our products, which could have a material adverse effect on our reputation and financial results. In addition, thefts at warehouses, at plants, or in transit of inventory that is not properly stored or that is sold through unauthorized channels could materially and adversely affect patient safety, our reputation and our results of operations.
Risks Relating to Our Business Strategies
We have substantial debt, including a significant amount incurred in connection with the Shire Acquisition, which may limit our ability to execute our business strategy, refinance existing debt or incur new debt, and if we are unable to meet our goals for deleveraging, we could be at a greater risk of a downgrade of our credit ratings.
Our consolidated bonds and loans were 4,635.4 billion JPY as of March 31, 2021, the majority of which was incurred in connection with the acquisition of the entire issued and to-be-issued share capital of Shire pursuant to a Scheme of Arrangement under the laws of Jersey (the “Shire Acquisition”) or represents the related indebtedness of Shire that is included in our consolidated statements of financial position, some of which was refinanced in the financial year. This significant amount of aggregate debt and the substantial amount of cash required for payments of interest and principal could adversely affect our liquidity. We are also required to comply with certain covenants within various financing arrangements and violations of such covenants may require the acceleration and immediate repayment of the indebtedness, which may in turn have a material adverse effect on our financial condition, cash flows, business and results of operations. Furthermore, we may desire to or be required from time to time to incur additional borrowings, including in relation to the repayment or refinancing of any of our currently outstanding indebtedness. Our ability to arrange new financing, or a re-financing and the terms thereof will depend on our financial position and performance, prevailing market conditions and other factors beyond our control. Moreover, if we decide to refinance indebtedness as it comes due, our overall leverage may not necessarily decrease.
While we have disposed of significant non-core assets since the Shire Acquisition and have primarily deployed the proceeds thereof toward deleveraging, such disposals may affect our business, financial condition or results of operations adversely, leading to larger-than-expected decreases in earnings.
Credit rating agencies routinely evaluate our business, and their ratings are based on a number of factors, including our leverage, ability to generate cash flows, overall financial strength and diversification, as well as other factors beyond our control, such as the state of the global economy and our industry generally. For example, we have announced our goals to reduce the extent of our leverage. If we are unable to decrease our leverage, we may be unable to improve our credit ratings or be subject to ratings downgrades or other adverse actions by third-party ratings agencies. While our credit ratings remain investment grade, each rating agency reviews its ratings periodically, and there is no assurance that the current credit ratings assigned to us will not be downgraded. A downgrade of our credit rating may materially and adversely affect the market prices of our equity and debt securities, including the notes, the interest rates at which our borrowings are made and debt securities are issued, and fees charged to us by current or future lenders. This could make it significantly more costly for us to borrow money, to issue debt securities and to raise certain other types of capital and/or complete additional financings. Such negative credit rating actions and the underlying reasons for such actions could materially and adversely affect our cash flows, results of operations and financial condition and the market price of, and our ability to pay the principal and interest on our debt securities.
12

We may fail to realize the anticipated benefits of the Shire Acquisition and expect to continue to record significant expenses related to it.
On January 8, 2019, we acquired the entire issued and to-be-issued share capital of Shire plc. The ultimate success of the Shire Acquisition depends on our ability to realize the anticipated growth opportunities and synergies leading to cost savings we expect from combining the companies’ businesses. The expected synergies of the Shire Acquisition and the projected cash costs necessary to achieve the synergies may be affected by changes in the overall economic, political and regulatory environment, including applicable tax regimes and fluctuations in foreign exchange rates, and the realization of the other risks relating to our business described herein.
Furthermore, in connection with the Shire Acquisition, we recorded significant intangible assets and, as a result, significant amortization expense in the fiscal years ended March 31, 2019, 2020 and 2021, and we expect to continue to record significant amounts of amortization expense in future fiscal years. We also recognized significant non-cash expenses relating to the unwinding of fair value adjustments to inventory as a component of cost of sales in the fiscal years ended March 31, 2019, 2020 and 2021; we expect to record a certain level of these expenses in the fiscal years ending March 31, 2022 and 2023. In addition, we recorded significant amounts of goodwill, and, if we are unable to achieve the anticipated benefits of the acquisition, we could be required to recognize significant impairment losses related to such goodwill and to intangible assets recorded in connection with the acquisition, potentially up to their full value. See “—We may have to recognize additional charges on our statements of profit or loss due to impairment of goodwill, other intangible assets and equity method investments.” for further discussion on risks associated with impairments.
We face risks from the pursuit of acquisitions, and the anticipated benefits and synergies resulting from acquisitions may not be realized.
We regularly pursue acquisitions for several reasons, including strengthening our pipeline, complementing existing lines of business, adding research and development capabilities or pursuing other synergies. The pursuit of these acquisitions requires the commitment of significant management and capital resources in various stages, from the exploration of potential acquisition targets to the negotiation and execution of an acquisition to the integration of an acquired business into our own. The required commitment of time and resources may divert the attention of management or capital or other resources away from our day-to-day business. Moreover, we may not be able to recoup the investment of capital or other resources through the successful integration of acquired businesses, including the realization of any expected cost or other synergies. Specifically, we may encounter the following difficulties: we may face significant challenges in combining the infrastructure, management and information systems of acquired companies with ours, including integrating research and development, manufacturing, distribution, marketing and promotion activities and information technology systems; there may be difficulties in conforming standards, controls, procedures and accounting and other policies, as well as business cultures and compensation structures; we may not be able to retain key personnel at acquired companies, or our own employees may be motivated to leave due to acquisitions; we may not be successful in identifying and eliminating redundancies and achieving other cost savings as expected; and we may not be able to successfully realize benefits from acquired products, including pipeline products under development.
Integrating the operations of multiple new businesses with that of our own is a complex process that requires significant management attention and resources. The integration process may disrupt our existing and other newly acquired businesses and, if implemented ineffectively, could have an adverse impact not only on our ability to realize the benefits of a given acquisition but also on the results of our existing operations. Integration-related risks may be heightened in cases where acquired businesses’ operations, employees or customers are located outside our major markets and we incur higher costs than anticipated due to regulatory changes, environmental factors or foreign exchange fluctuations. We continue to pursue strategic business acquisitions globally as a key part of our continuous growth strategy. If we are not able to achieve the anticipated benefits of any future acquisitions in full or in a timely manner, we could be required to recognize impairment losses, we may not be able to recoup our investment, and our business, financial position and results of operations could be materially and adversely affected. Particularly, we may be unable to achieve the expected revenues pursuant to licensing, co-promotion or co-development agreements or collaborations. We may also assume unexpected contingent or other liabilities, or be required to mark up the fair value of liabilities (or mark down the fair value of assets) acquired upon the close of an acquisition.
We have significant operations across the world, including emerging markets, and continued expansion into new and developing markets is a key strategy, which expose us to additional risks.
Our global operations, which encompass approximately 80 countries and regions across the world, are subject to a number of risks, including difficulties in monitoring and coordinating research and development, marketing, supply-chain and other operations in a large number of jurisdictions; risks related to laws, regulations and policies, including those implemented following changes in political leadership and trade, capital and exchange controls; changes with respect to taxation, including impositions or increases of withholding and other taxes on remittances and other payments by our overseas subsidiaries; varying standards and practices in the legal, regulatory and business cultures in which we operate, including potential inability to enforce contracts or intellectual property rights; trade restrictions and changes in tariffs; complex sanctions regimes in various countries such as the U.S., the EU and other jurisdictions, violations of which could lead to fines or other penalties; risks related to political instability and uncertain business environments; changes in global, regional or local economies, or the overall political, economic or social climate, including inter-country relationships; acts of terrorism, war, global climate change, extreme weather events, medical epidemics or pandemics such as the recent COVID-19 pandemic, and other sources of social disruption; and difficulties associated with managing local personnel and preventing misconduct by local third-party alliance partners.
Any one or more of these or other factors could increase our costs, reduce our revenues, or disrupt our operations, with possible material adverse effects on our business, financial condition and results of operations. Further expansion overseas has been one of our key strategies, and, in
13

the fiscal year ended March 31, 2021, regions outside of Japan accounted for 82.5% of our consolidated revenue, with the U.S. in particular contributing 49.0% of consolidated revenue. We expect that markets outside Japan, particularly the U.S. and also Europe and Canada, will continue to be increasingly important to our business and results of operations, increasing the likelihood that any of these risks is realized. We have also been taking steps to grow our business in emerging markets, which we define to include Russia/Commonwealth of Independent States (“CIS”), Latin America, Asia (excluding Japan) and Other (including the Middle East, Oceania and Africa). Our revenue from emerging markets was 404.0 billion JPY (or 12.6% of our total revenue) for the fiscal year ended March 31, 2021, and we intend to pursue further growth in such emerging markets. In particular, we believe that there is an attractive opportunity to grow our business in China.
However, there is no guarantee that our efforts to expand sales in emerging markets will succeed. Some countries may be especially vulnerable to periods of global financial instability or may have very limited resources to spend on healthcare. Emerging markets present particular challenges in obtaining funding, achieving market access for our products and successfully ensuring that we receive appropriate levels of reimbursement. Emerging markets also tend to require substantial efforts in patient support and other programs. All of these factors may adversely affect the profitability of our businesses in these emerging markets.
In order to successfully implement our emerging markets strategy, we must also attract and retain qualified personnel, despite the possibility that some emerging markets may have a relatively limited number of persons with the required skills and training. We may also be required to increase our reliance on third-party agents within less-developed markets, which may put us at increased risk of liability. In addition, many emerging markets have currencies that fluctuate substantially, and if such currencies are devalued and we cannot offset the devaluations, our financial performance in such countries may be adversely affected. Further, many emerging markets have relatively weak intellectual property protection and inadequate protection against crime, including counterfeiting, corruption and fraud. Operations in certain emerging countries, where corruption may be more prevalent than in more developed countries and where internal compliance practices may not be well established, may also pose challenges from a legal and regulatory compliance perspective. Moreover, we may face additional legal and regulatory barriers to achieving growth, such as restrictions on the import of raw materials or other trade regulations (for example, on the import of plasma into China) that will require us to expend additional resources to achieve our goals.
For reasons including but not limited to the above, significant parts of our operations across the world including emerging markets presents significant risks, and the realization of such risks could have a material adverse effect on our business, financial condition and results of operations.
We may experience difficulty implementing sustainability-related measures, particularly those relating to the environment, or in meeting the expectations of stakeholders.
Governmental and regulatory authorities, counterparties such as vendors and suppliers, investors, the public at large and others have increasingly focused on sustainability and social responsibility-related issues, particularly as they relate to the environment. Moreover, we have established a company-wide sustainability program, and as part of this program, we have committed to reducing our carbon footprint, decreasing the waste created by our business and enhancing our water stewardship, and expect our vendors and suppliers to cooperate in these initiatives. Particularly, we announced that we would become carbon neutral and implement a long-term strategy to reduce companywide emissions to zero by 2040. However, we may be unable to meet such standards or achieve our goals, and our efforts to do so may for example impose significant additional costs on us, require us to seek alternative vendors or suppliers or impair our ability to procure or use certain materials. Conversely, if we are unable to meet such standards, we may not be able to continue to administer our manufacturing, research and development or other aspects of our business as we desire. Moreover, to the extent that we are unable to meet the expectations of stakeholders, including governmental and regulatory authorities, counterparties, investors, or the public, our reputation may be harmed, we may face increased compliance or other costs and demand for securities issued by us and our ability to participate in the debt and equity markets may decrease. Furthermore, such standards and expectations are subject to ongoing change and refinement, and may shift in unexpected and potentially significant ways, which we may struggle to accommodate.
Our digital transformation initiatives may be unsuccessful, and our profitability may be hurt or our business otherwise might be adversely affected.
We have made and plan to continue to make significant investments in digital transformation initiatives, with the goal of modernizing our platforms, accelerating data services, enhancing our ability to innovate and equipping our employees with new skills and ways of working. These types of activities are complex and are dependent on a number of factors, including entering into successful partnerships and alliances with technology companies, as well as developing and deploying technology architecture successfully. If we do not successfully manage our digitalization initiatives, or any other related activities that we may take in the future, any expected efficiencies and benefits might be delayed or not realized, and our operations and business could be disrupted. If we fail to adequately integrate digitalization into our business, we may lose patients and market share. Even if our efforts are successful, our competitors, including established competitors or new entrants with specialized expertise, may be better able to achieve digitalization and realize its benefits, giving them a competitive advantage over us, displace any technology that we may develop or implement or make them obsolete. In addition, the costs associated with implementing these initiatives might exceed expectations, which could result in additional future charges, and we may be exposed to increased cybersecurity or related risks. The occurrence of any of these risks could have a material adverse effect on our business, financial position and results of operations.
We are increasingly dependent on information technology systems and our systems and infrastructure face the risk of theft, exposure, tampering or other intrusions.
A variety of important processes relating to the research and development, production and sale of our products depend heavily on our information systems, including cloud-based computing, or those of third party providers to whom we outsource certain business functions, including the storage and transfer of critical, confidential, sensitive or personal information regarding our patients, clinical trial subjects, vendors, customers,
14

employees and others. We also increasingly seek to develop and collaborate on technology-based digital health products, such as mobile applications that aim to improve patient welfare in a variety of ways, which could lead us to store and transfer personal information about individual patients, customers and others. The size, age and complexity of our information technology systems make them potentially vulnerable to service interruptions, malicious intrusions and random attacks. Cyber-attacks are increasing in frequency, sophistication and intensity, and opportunistically in response to, for example, the spread of COVID-19 and implementation of remote working arrangements. These and other cyber-attacks are made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, hacktivists, nation-states and others. Cyber-attacks could include the deployment of harmful malware, denial of service attacks, worms, social engineering and other means to affect service reliability and threaten data confidentiality, integrity and availability. The development and maintenance of systems to safeguard against such attacks is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become increasingly more sophisticated. Moreover, the costs related to these security measures are expected to continue to increase. Despite our efforts, the possibility of a future data compromise cannot be eliminated entirely, and risks associated with intrusion, exposure, tampering, and theft remain. For zero-day threats, or new vectors of attack which are currently unknown, the risk that our defenses will be inadequate are particularly pronounced.
Although we have not, to date, detected any material breaches of our information technology systems, data systems or personal information, the risk of such breaches remains and cannot be comple